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INTRODUCTION 
1. Melanoma 
1.1 Etiology and Epidemiology 
Melanoma is the least common but the most 
aggressive form of skin cancer occurring when melanocytes, 
melanin-producing cells of the skin, eye, mucosal epithelia, 
and meninges undergo changes and become malignant. So, 
melanoma may occur in all parts of the body where are 
normally present melanocytes, as the skin of course, but also 
the mucous membranes, meninges and uvea. Has greater 
impact on the left side of the body1. Melanocytes are derived 
from neural crest progenitors, and their development is 
modulated by the receptor tyrosine kinase (RTK) c-KIT and 
microphthalmia-associated transcription factor (MITF). 
Melanocytes produce two main types of pigment: 
brown/black eumelanin, that protects from ultraviolet 
radiation (UVR) and red pheomelanin that contributes to 
melanomagenesis through a mechanism involving ROS2-3. 
Genetic predisposition or an environmental stressor 
contributes to the genesis of melanoma. The strongest 
melanoma risk factors are a family history of melanoma, 
atypical moles or dysplastic nevi. Sun sensitivity, 
immunosuppression and exposure to ultraviolet radiation 
are additional risk factors4. In particular the exposure to 
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ultraviolet light causes variations in particular genes 
(polymorphisms) that affect both the defensive response of 
the skin to ultraviolet light and the risk of melanoma. 
Ultraviolet radiation has multiple effects on the skin: causes 
genetic changes, impairs cutaneous immune function, 
increases the local production of growth factors, and induces 
the formation of DNA-damaging reactive oxygen species that 
affect keratinocytes and melanocytes5. Clinically, variations 
in pigmentation and the protective response to ultraviolet 
light are associated with variations in susceptibility to 
melanoma. Also, specific phenotypic characteristics have 
been shown to correlate with increased risk of melanoma 
such as green/blue eye color, red/blond hair color, fair skin, 
the presence of freckles and inability to tan. Caucasians have 
a 20-fold increased risk of developing skin melanoma when 
compared to dark skin populations6.  
According to the World Health Organization, in the 
last decades the incidence of cutaneous malignant melanoma 
is increasing faster than any other cancer in the world, about 
of 2-7% annually. This fact has led to the use of the term 
melanoma “epidemic”7. In 2014 the American Cancer Society 
and the National Cancer Institute estimated 76,100 new 
cases of patient with invasive melanoma and 9,710 deaths 
only in USA. Although melanoma represent less of 5% of 
cases of skin cancer it counts more of 75% of skin-related 
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deaths8. Melanoma is very common in young adults aged 15-
34 years. Melanoma incidence is also dependent on gender, 
infact in the U.S. women have a higher risk of melanoma than 
men before age 40, but they have a better prognosis in term 
of survival. In men, the predominant anatomical location for 
melanoma lesions is the trunk and in women lesions are 
mainly found in the lower limbs9. This impressive increase 
in incidence may be due to several factors, including 
behavioural changes, better early detection by screening 
instruments, changes in diagnostic criteria in 
histopathology, and perhaps also the change in the medico-
legal climate10. 
A simple procedure to diagnose melanoma is founded 
on its pigmentation. The American Cancer Society has 
devised a simple A-B-C-D-E acronym to guide in the 
identification of pigmented lesions that should be evaluated 
with biopsy (Figure 1).  
A = asymmetry, when one half the lesion is looking different 
from the other half; the common nevi are round and 
symmetrical whereas the most melanomas is asymmetric. 
B = border irregularity, the common nevi have smooth 
edges whereas margins of melanomas in the initial phase are 
often irregular and jagged. 
C = color variegation, the common nevi have the same 
shade of brown whereas the lesion is not one uniform color 
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but rather a combination of black, brown, blue, or even 
white. 
D = diameter, lesions whit a diameter greater than 5-6 mm 
is exposed to a higher risk of turning into melanoma. 
E = evolution or enlargement, any change or evolution of a 
previously present pigmented lesion should raise suspicion 
for the lesion being melanoma and trigger a biopsy. 
 
 
 
Figure 1. The ABCs of Melanoma Diagnosis 
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1.2 Stadiation 
The Clark model describes the histopathological 
changes that occur in the progression of melanoma, from 
normal melanocytes to malignant. In the Clark model, the 
first phenotypic change in melanocytes is the development 
of benign nevi, which are composed of neval melanocytes 
(Figure 2). Normal melanocytes progressively develop a 
malignant phenotype through the acquisition of various 
phenotypic features. The particular histologic features 
characterizing each step of progression are the visible 
manifestations of underlying genetic changes. When the 
growth of a nevus is controlled, probably by the oncogene-
induced cell senescence, they rarely progresses to cancer. 
Instead, abnormal activation of the mitogen-activated 
protein kinase (MAPK) signaling pathway due to somatic 
mutations of N-RAS or BRAF stimulates growth in melanoma 
cells. These mutations occur at a similar frequency in benign 
nevi and in primary and metastatic melanomas. So most nevi 
stop proliferation and remain static for decades, other may 
acquire additional molecular lesions and become malignant.  
The second step in the progression of melanoma is 
the trasformation of some benign nevi in dysplastic nevi, 
which are not really invasive malignancies, but rather just 
moles that have some architectural disorder. The third step 
is the radial growth phase melanoma in which there is 
10 
growth through the epidermis but not deeply into the 
dermis. In the fourth step, namely vertical-growth phase, 
appear the invasive characteristics of the melanoma cells. 
They acquire a potential to spread, grow intradermally and 
gains the capacity to invade the vascular and lymphatic 
systems.  
Finally, a metastatic melanoma develops when tumor 
cells dissociate from the primary lesion, migrate through the 
surrounding stroma, and invade blood vessels and 
lymphatics to form a tumor at a distant site, whether it be in 
an organ, or a skin, or lymph node through vascular or 
lymphatic invasion11.  
 
 
 
 
Figure 2. Biologic Progression of Melanoma 
(Miller et al., N Engl J Med 2006) 
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The Breslow model measures the melanoma 
thickness (in millimetres) as the distance between the upper 
layer of the epidermis and the deepest point of tumor 
penetration. Tumor depth is most accurately measured by 
evaluating the entire tumor via an excisional biopsy. 
Clinically, the Breslow index is considered one of the most 
significant factors in predicting the progression of the 
disease and primary criterion in melanoma staging12 (Fig. 3).  
 
 
 
 
 
Figure 3. Clark and Breslow’s model 
 (Miller et al., N Engl J Med 2006) 
 
 
 
 
 
 
 
The current melanoma staging refers at the seventh 
edition (2209) of the American Joint Committee on Cancer 
(AJCC) Cancer Staging Manual that was made on the basis of 
a multivariate analysis of 30,946 patients with stages I, II, 
and III melanoma and 7,972 patients with stage IV 
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melanoma. In this system histological features as tumor 
thickness, mitotic rate, and ulceration, are important 
hallmarks of melanoma prognosis and staging.   
According to AJCC the melanoma stages are classified 
as reported: 
STAGE 0: In situ (non-invasive) melanoma remains confined 
to the epidermis. 
STAGE I and II: Localized Melanoma. These stages are 
divided each other in: Stage IA-IB and IIA-IIB-IIC on the base 
of tumor thickness “T” (thresholds of 1.0, 2.0, and 4.0 mm) 
and the presence of microscopic ulceration. The presence of 
at least one mitosis (cancer cell division) per millimeter 
squared (mm2) can upgrade a thin melanoma to a later stage 
at higher risk for metastasis. 
STAGE III: Regional Metastatic Melanoma. These stages are 
divided each other in: Stage IIIA-IIIB-IIIC on the base of 
number of nodal metastases “N” (thresholds of 1, 2-3 and 4+ 
nodes, depends on factors such as whether the metastases 
are in-transit or have reached the nodes, the number of 
metastatic nodes, the number of cancer cells found in them) 
and micrometastases. This can be determined by examining 
a biopsy of the node nearest the tumor, known as the 
sentinel node.  
STAGE IV: Distant Metastatic Melanoma, defined on the 
evaluated of the site(s) of the distant metastases “M” 
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(nonvisceral, lung, or any other visceral metastatic sites) and 
elevated serum lactate dehydrogenase (LDH) level (Table 1 e 
2).  
 
 
Table 1. TNM Staging Categories for Cutaneous Melanoma 
(Balch et al., J Clin Oncol. 2009) 
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Table 2. Anatomic Stage Groupings for Cutaneous      
Melanoma (Balch et al., J Clin Oncol. 2009) 
 
 
As with nearly all malignancies, the outcome of 
melanoma initially depends on the stage at presentation. An 
estimated 82% to 85% of patients present with localized 
disease, 10% to 13% with regional disease, and 2% to 5% 
with distant metastatic disease. In general, the prognosis is 
excellent for patients who present with localized disease and 
primary tumours 1.0 mm or less in thickness, with 5-years 
survival achieved in more than 90% of patients. For patients 
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with localized melanomas more than 1.0 mm in thickness, 
survival rates range from 50% to 90%. The likelihood of 
regional nodal involvement increases with increasing 
tumour thickness. When regional nodes are involved, 
survival rates are roughly halved. However, within stage III, 
5-year survival rates range from 20% to 70%, depending 
primarily on the nodal tumour burden. Long-term survival 
in patients with distant metastatic melanoma, taken as a 
whole, is less than 10%. However, even within stage IV, 
some patients have a more indolent clinical course that is 
biologically distinct from that of most patients with 
advanced disease13. 
 
1.3 Molecular pathways activated  in melanoma 
Cell signaling pathways regulate cell growth and 
death, cell metabolism migration and angiogenesis. In cancer 
progression there is a loss of control of these signalling that 
result hyperactivated and/or silenced irreversibly allowing 
to cancer cells to acquire specific phenotypes, such as the 
ability to resist to apoptosis, abnormal proliferation, 
angiogenesis, and invasion.  
 
RAS/RAF/MEK/ERK pathway 
The mitogen-activated protein kinase (MAPK) 
pathway plays an important role in cellular proliferation and 
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differentiation. Under normal physiological conditions 
growth factors bound their tyrosine kinases receptors and 
activate a small GTP binding protein RAS (existing in three 
isoform: ARAF, BRAF and CRAF in humans) on cell 
membranes, which triggers intracellular signaling. This is 
followed by the sequential stimulation of several 
cytoplasmic protein kinases. The first of the cascade is RAF, 
a serine/threonine kinase protein that leads to 
phosphorylation of MEK (mitogen-activated protein/ERK 
kinase) proteins that activate in highly specific manner the 
downstream components: the extracellular signal-related 
kinase-1 and 2 (ERK-1 or p44 MAPK and ERK-2 or p42MAPK). 
These isoforms can be activated in response to a wide 
variety of growth factors and mitogens such as stem cell 
factor (SCF), fibroblast growth factor (FGF), hepatocyte 
growth factor (HGF), and glial-cell-derived neurotrophic 
factor (GDNF) as a result of phosphorylation of threonine 
and tyrosine residues in a -TXY- motif and then translocate 
into the nucleus and stimulate pro-growth signals. In 
particular, the main substrates of ERKs are the transcription 
factors and other nuclear proteins like c-Fos ATF-2, c-Myc, c-
Myb, Ets2, NF-1L6, TAL-1 and p53. In addition to transcription 
factors, another set of substrates for the ERKs are PHAS, 
tyrosine hydroxylase, phospholipase A2, phospholipase Cy, 
RNA polymerase II, CDC2 and also apoptosis regulator protein 
17 
as Bim, Bax, Bcl-2, Bad. Therefore, ERK activation promote 
cell-cycle progression and proliferation
14
.  
Unregulated activation of the MAPK pathway can lead 
to malignancy. The MAPK pathway is one of the most 
frequently deregulated signaling pathways in the great 
majority of melanomas. ERK is hyperactivated in 90% of 
human melanomas by growth factors and by genetic 
alterations of upstream factors, RAS and RAF proteins as 
well as mutations at upstream membrane receptors (e.g., 
KIT) 15. Mutations in BRAF appear to be the most common 
genetic alteration and major driver of this pathway, which 
occur in 50–70% of melanomas. Although BRAF is thought 
to exert its oncogenic effects almost entirely through MEK, 
CRAF can lead to MEK-independendent pro- survival effects, 
in part through its interaction with nuclear factor-kappa  B 
(NF-B), as well  as through  inhibitory effects  of critical 
regulators   of   apoptosis,   such   as   ASK-1   and   MST-216-
17. These mutations can be identified in benign melanocytic 
proliferation and all stages of invasive and metastatic 
melanoma promoting proliferation, survival, invasion, and 
angiogenesis of melanoma. Specifically, the presence of a 
BRAF mutation has been associated with a more aggressive 
disease course and poorer prognosis compared with 
patients without BRAF mutations18.  
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In melanoma, NRAS gene also is mutated in 15-30% 
of tumor samples leading to its permanent activation and 
serial activation both the downstream components of the 
RAS effector pathways and the non-MAPK pathways, such as 
the phosphatidylinositol-3 kinases (PI3K) pathway resulting 
in increased v-akt murine thymoma viral oncogene homolog 
(AKT) activity19-20.  
 
PI3K/AKT/mTOR pathway 
The PI3K/AKT/mTOR is an intracellular signaling 
pathway promoting cell survival and proliferation, and is 
hyperactivated in most malignancies, including melanoma21-
22.  Stimulation of the PI3K pathway arises via GTP binding of 
RAS proteins and stimulation of receptor tyrosine kinases 
(RTKs). PI3Ks, constitute a lipid kinase family characterized 
by their ability to phosphorylate inositol ring 3′-OH group in 
membrane phospholipids generating phosphatidylinositol-
3,4-bisphosphate (PIP2) and phosphatidylinositol-3,4,5-
trisphosphate (PI-3,4,5-P3) which is a key propagator of 
intracellular signaling.  
 AKT is a family of serine/threonine protein kinase 
that comprise three highly homologous members known as 
AKT1, AKT2 and AKT3. All three AKT isoforms consist of a 
conserved domain structure including a specific PH domain, 
a central kinase domain and a carboxyl-terminal regulatory 
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domain that mediates the interaction between signaling 
molecules. AKT normally exist in the cytoplasm in inactive 
conformation. After the interaction with PIP3 by its PH 
domain it traslocates to the inner membrane where it is 
phosphorylated in two critical residues, Thr308 and Ser473. 
Thr308 is in the activation loop within the kinase domain of 
AKT and it is phosphorylated by PDK1 (phosphoinositide-
dependent kinase 1). Ser473 is in the C-terminal regulatory 
domain of AKT and it is phosphorylated by mTORC2 
complex. Phosphorylation of Thr308 partially activates AKT, 
while phosphorylation of both sites is required for full 
activation. The numerous substrates of AKT include cellular 
regulators of insulin signaling, proliferation, and survival23-
24. AKT is inactivated by phosphatases (PP2A, PHLPP1, and 
PHLPP2) that remove the phospho-group from these 
residues. The activity of the PI3K/AKT pathway overall is 
regulated by the tumour suppressor phosphatase and tensin 
homolog (PTEN).  
PTEN dephosphorylates the 3’ position of PIP2 and PIP3 
antagonizing PI3K activity. Activated AKT phosphorylates a 
broad range of proteins involved in the control of apoptosis 
(the FOXO family of transcription factors, BAD or NF-κB), 
cell cycle regulation (GSK3β, p27kip1), and growth (TSC2)25, 
thereby facilitating the proliferation and survival of cells.  
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mTOR (mammalian target of rapamycin), a 
serine/threonine protein kinase, is a downstream effector of 
PI3K and AKT. mTOR carries out several function via two 
different complexes, mTOR complex 1(mTORC1) and mTOR 
complex 2(mTORC2). mTORC1 includes mTOR regulatory-
associated protein of mTOR (Raptor), mLST8, and proline-
rich AKT substrate 40 (PRAS40)26 and is allosterically 
inhibited by the macrolide antibiotic rapamycin27.  It is an 
important effector of cell growth and proliferation and 
regulates protein synthesis acting on several components of 
the translation machinery as eukaryotic translation 
initiation factor (eIF4E) and p70S6 kinase28. mTORC2 
includes rapamycin-insensitive companion of mTOR 
(Rictor), mLST8, and stress-activated MAPK-interacting 
protein 1 (Sin1)29. It plays important roles in signal 
transduction as well as activates directly AKT30.  
The major mechanisms of PI3K pathway activation in 
melanoma are loss of PTEN and NRAS mutations. Lack of 
PTEN antagonism (observed in 12% of melanomas through 
mutation or methylation) causes increased levels of PIP3 
and active (phosphorylated) AKT31. Mutated AKT may also 
independently activate the PI3K/AKT/mTOR signalling 
pathway. Elevated AKT phosphorylation and/or activated 
mTOR functioning arises in 70% of malignant melanomas32-
33. In particular, increased levels of the active form of AKT 
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were found in the radial-growth phase of melanoma and was 
found correlate with poor prognosis in melanoma patients34-
35. Activation of AKT in cancer cells induces cell survival, 
proliferation, metastais, invasion, and angiogenesis. AKT, 
infact, inhibits apoptosis through the inactivation of BCL-2 
antagonist of cell death (BAD) protein and of caspase-9, and 
promotes cell proliferation by increasing CCND1 expression. 
Moreover, affects many other cell-survival and cell cycle 
genes through the activation of transcription factor as NF-
B36-37.  
 
NF-κB pathway 
Nuclear Factor-kappa B (NFκB) is an inducible 
transcription factor that regulates the expression of many 
genes involved in the immune response.  
The NF-κB proteins constitute a family of proteins with 
homology to the chicken oncogene, rel. There are five known 
mammalian NF-κB subunits, each characterized by ankyrin 
repeat elements: p65 (RelA), RelB, Rel (c-Rel), p50/p105, 
and p52/p100 which form homo- and hetero-dimers. These 
proteins share an approximately 300 amino acid N-terminal 
domain called the Rel homology (RH) domain containing 
important sequences for binding DNA or inhibitor of NF-B 
(IB) as well as sites of dimerization. However, they differ in 
their C-terminal domain in that RelA, RelB and c-Rel exhibit 
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transactivating functions, while p100 and p105 contain 
inhibitory domains. In fact, NF-B1/p105 and NF-B2/p100 
are the inactive precursors of the p50 and p52 proteins, 
respectively. The most common Rel/NF-κB dimer in 
mammals contains p50-p65. In unstimulated cells, NF-B is 
retained in the cytoplasm through interaction with 
inhibitory proteins called IBα (nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, α). NF-B 
activation is rapidly induced by primarily inflammatory 
stimuli, as well as proinflammatory cytokines (IL-1 and TNF-
, endotoxins, viruses and UV, that lead to activation of the 
IB kinase (IKK) complex. IKK activated phosphorylates IκB 
proteins that are recognized by the ubiquitin ligase 
machinery, leading to their polyubiquitination and 
subsequent degradation by the proteasome 26S. During this 
process, also p65 is phosphorylated and p100 and p105 are 
cleaved into active forms p52 and p50 respectively. These 
events generate active NF-κB complexes that is free to 
traslocate into the nucleus where they bind to specific 
sequence in the promoters of target genes, inducing 
transcription38. These genes include: immunoregulatory and 
inflammatory genes (cytokines and chemokines, acute phase 
proteins, cell adhesion proteins, inducible nitric oxide 
synthase (iNOS), immunoglobulins, and viral genes; anti-
apoptotic genes as tumor necrosis factor receptor-associated 
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factor 1 and 2 (TRAF1 and TRAF2)  inhibitor-of-apoptosis 
protein 1 and 2 (c-IAP1 and c-IAP2), caspase8/FADD, c-FLIP, 
members of BCL2 family; genes that positively regulate cell 
cycle progression (cyclin D1, c-myc, MMP9); and genes that 
encode negative regulators of NF-κB39-40.  
The earliest indication for its role in tumorigenesis was 
emerged following RelA/p65 cloning and sequencing, which 
revealed its homology to c-Rel and its viral oncogenic 
derivative v-Rel that leads to carcinogenesis in avian 
lymphoid cells41. Recently, NF-κB activity has been shown to 
be upregulated in many cancers, including melanoma. It was 
demonstrated that some components of NF-κB family, such 
as p50 and p65 are overexpressed in the nuclei of dysplastic 
nevi and lesions of human melanoma42. The activation of NF-
κB promotes the multiple steps in melanoma progression 
such as transformation, initiation, promotion, angiogenesis, 
invasion and enhanced metastatic potential of malignant 
melanoma cells43. Moreover, NF-B activated would be 
responsible of resistance of cancer cells to chemotherapeutic 
agents44. NF-κB activation in melanoma may be the result of 
either exposure to proinflammatory stimuli in the tumor 
microenvironment or mutational activation of IKK resulting 
in enhanced transactivating capacity of the NF-B complex 
and an increased survival of melanoma cells45.  
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Data indicate that the enhanced activation of NF-κB may be 
due to deregulations in upstream signaling pathways such as 
Ras/Raf and PI3K/AKT46. It has recently been suggested that 
AKT phosphorylates IKKα at the consensus sequence 
RXRXXS/T, leading to the p65 phosphorylation and also may 
facilitate directly the phosphorylation of p65 on serines 529 
and 53647. Mutational activation of BRAF, common in human 
melanomas, has been also associated with an enhanced IKK 
activity and the activation of NF-κB transcriptional activity 
resulting in increased survival of melanoma cells48. Infact, 
constitutively active ERK may indirectly activate NF-κB 
through the upregulation of inflammatory cytokines such as 
TNF-α and IL-1α/β, as well as chemokines, that activateNF-
κB49-50. 
Therefore, NF-κB is a downstream target of both RAF 
and AKT and the PI3K/AKT pathway can activate by 
oncogenic RAS51-52. The extensive interaction of these 
signaling pathways in malignant melanomas provides a 
possible mechanism for compensatory signaling to make 
resistance to molecular-targeted therapy (Figure 4). 
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Figure 4.  Signaling pathways activated in melanoma       
                    (Strickland et al., Cancer letters, 2015) 
 
 
 
 
1.4 Common genetic alteration in melanoma 
The development and progression of malignant 
melanoma is relate to gene mutations. In recent years, next-
generation sequencing of melanoma has revealed the 
enormous genetic complexity of melanoma, with thousands 
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of mutations, deletions, amplifications, translocations, and 
DNA methylation changes being present in the genomes of 
individual tumors. The mutation rate of melanoma is higher 
than those reported for other aggressive tumors (Table 3). 
This may due to the mutagenic effect of ultraviolet (UV) 
radiation involved in the melanoma pathogenesis53. Infact, a 
recent analysis of whole-exome sequences revealed that 
46% of melanoma driver mutation can be attributed to the 
cytidine to thymidine (C-to-T) transition, characteristic 
alteration due to UVR; a 9% of melanoma driver mutations, 
instead, showed the guanine to thymidine (G-to-T) 
transversion, characteristic of UVA-associated oxidative 
damage. Most of these occur in tumour suppressor genes, 
including CDKN2A, PTEN, and TP53. However, although UVR 
cause many mutations, other mutagenic mechanisms are 
likely important in melanoma development54. Melanoma 
mutations it must be differentiated which mutations is 
causative in the disease “driver mutations” (confer a fitness 
advantage to the tumor cell) and which is only a bystander 
mutation “passenger mutations” (that never conferred a 
fitness advantage)
 55
. 
One of the best-studied oncogenic events in 
melanoma is mutation of BRAF (v-Raf murine sarcoma viral 
oncogene homolog), a key protein kinase acting in the RAS–
RAF–MEK–ERK mitogen-activated protein kinase (MAPK) 
27 
signal transduction pathway which regulates cell growth and 
proliferation. The RAF isoforms include ARAF, BRAF, and 
CRAF/RAF-156. BRAF mutations are found in about 60% of 
all melanomas and in most of the benign nevi, which implies 
that the mutation by itself is not responsible for malignancy 
in melanocytic proliferations. BRAF mutations are more 
frequent in melanomas that develop in intermittently sun-
exposed skin and less so in acral and mucosal melanomas. 
BRAF mutations are not found in uveal melanomas57. The 
most common mutation of BRAF are found in exon 15, at 
codon 600. In about 75% of all mutations in that area a 
valine is substituted by glutamic acid at codon (V600E). Less 
common mutations include valine by lysine (V600K) (about 
20%), valine by aspartic acid (V600D) and valine by arginine 
(V600R) contribute another 5–6%. All this BRAF mutation 
cause the permanent activation of the protein and 
consequently induce MEK activation58. BRAF mutation, and 
in part also the special type of substitution, correlates with 
age, localization of the primary tumor, sun damage, and, in 
part, geographic region. A small number of BRAF mutants 
other than V600 were identified in human melanoma, as 
G469E, D594G, G466A, and N581S. These mutants have low 
kinase activity but shown to still activate ERK via a 
mechanism involving their ability to strongly activate 
CRAF59. Melanomas with wild type BRAF usually carry 
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oncogenic mutations in upstream components of the MAPK 
pathway.  
NRAS (neuro-blastoma RAS viral oncogene homolog), 
a GTPase is mutated in approximately 20% of melanomas60.  
KIT (v-Kit Hardy–Zuckerman 4 feline sarcoma viral 
oncogene homolog) is a receptor tyrosine kinase activated 
by binding of the cytokine stem cell factor (SCF); in 
melanoma KIT mutation and amplification are quite rare, 
they are found in particular subsets of melanoma, acral 
melanoma, mucosal melanoma, and lentigo maligna 
melanoma61. Approximately 70% of KIT mutations identified 
in melanoma are found in exon 11, most commonly L576P, 
and in the kinase domain in exon 13, most often K642E62. 
KIT mutations activate signal-transduction pathways (MAPK 
and PI3K) and increased melanocyte proliferation and 
melanoma survival63.  
GNAQ (guanine nucleotide-binding protein, q 
polypeptide) and GNA11 (guanine nucleotide-binding 
protein, a11), encoding members of the Gα (q) family of G 
protein α subunits, are driver oncogenes in uveal melanoma. 
Mutations in GNAQ and GNA11activate the MAPK pathway64-
65.  
Genetic alterations in components of the p16INK4A–
cyclin D/CDK4-RB cell cycle checkpoint are found in 
virtually all melanoma cell lines in a mutually exclusive 
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fashion, underlining the importance of this checkpoint in 
preventing melanoma development66-67. CDKN2A is a well-
known melanoma tumor suppressor gene that encodes for 
two tumor suppressor proteins through alternative splicing: 
p16INK4A, a key negative regulator of the cell cycle that 
activates retinoblastoma protein (RB) through negative 
regulation of CDK4, and p14ARF which activates p53 
through inhibition of its major negative regulator, MDM268. 
CDKN2A locus is mutated in about 25% of melanoma 
families and inactivated by mutation, deletion, or promoter 
hypermethylation in 50–80% of sporadic melanoma cases69. 
Loss of CDKN2A and CCND1 correlate with poor responses 
to dabrafenib70. Moreover, expression of oncogenic 
BRAFV600E in melanocytes induces expression of 
p16INK4A71. p53 mutations was found in 19% of melanoma 
tumors72, but several alterations in other genes affecting p53 
activity inhibiting its function. Other known genetic 
alterations are: mutation of p14ARF73; overexpression of 
MDM2 or amplification of MDM4, the major negative 
regulators of p53 that promote its degradation and 
inactivation74-75; overexpression of p63, an antiapoptotic 
protein related to p53 that in melanoma cell lines prevents 
translocation of p53 to the nucleus76; increased expression 
of iASPP, a conserved ankyrin repeat protein that shuttles 
between nuclear and cytoplasmic compartments and 
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inhibits the pro-apoptotic function of p5377. CDK4, a cell 
cycle G1/S kinase, and cyclin D1 (CCND1), were shown to be 
amplified in melanoma78. CDK4 mutations are associated 
with familial melanoma79. Significantly, CDK4 pathway is 
deregulated in most melanomas as a consequence of 
increased activity of ERK or deletion of CDK4 inhibitor 
p16INK4A. 
A cooperating event in BRAF-initiated melanomagenesis is 
constitutive activation of the PI3K/AKT/mTOR signaling 
pathway. BRAFV600E mutation are often associated with 
the PTEN aberrations inducing hyperactive–mTOR signaling 
in melanomas.  
PTEN is a negative regulator of the PI3K/AKT 
pathway and it is mutated in 25% to 30% of melanoma, 
most commonly via allelic loss and focal deletions80. PTEN 
(or rather lack of PTEN) was shown to play a key role in the 
predisposition to melanoma in individuals carrying certain 
variants of melanocortin-1 receptor (MC1R). The 
mechanisms through which MC1R variants associated with 
red hair and fair skin predispose to melanoma were not 
understood until recently, when it was shown that wild-type 
but not variant MC1R protein associates with PTEN and 
protects it from degradation after UVB exposure. Disrupted 
MC1R-PTEN association was shown to be responsible for the 
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oncogenic transformation promoted by MC1R variants in 
presence of BRAFV600E81. 
By contrast, activating mutations in PIK3CA, which 
encodes the catalytic subunit of PI3K, or in AKT1, AKT2, and 
AKT3, are rare in melanoma82. Only AKT3 is deregulated in 
25% of melanoma tumours promoting development of 
malignant melanoma83. Mutations in other PI3K pathways 
genes mTOR, IRS4, PIK3R1, PIK3R4, and PIK3R5 were 
detected in 17% of BRAFV600 and in 9% of NRAS-mutant 
tumors84. 
Phosphoinositide-dependent kinase-1 (PDK1) is a 
serine/threonine protein kinase that phosphorylates and 
activates kinases of the AGC family, including AKT. Increased 
expression of PDK1 was observed in a large cohort of 
melanoma samples compared to nevi, and deletion of PDK1 
in a GEMM of melanoma BRAFV600E/PTEN-/- significantly 
delayed development of tumours and metastases85.  
MAP2K1 and MAP2K2 (MEK1 and MEK2, 
respectively) was found mutated in several melanoma cell 
lines whit a frequency of 8%, resulting in constitutive ERK 
phosphorylation and higher resistance to MEK inhibitors86.  
Microphthalmia-associated transcription factor 
(MITF) is a survival oncogene, amplified in 20% of 
melanoma cases. MITF acts both as a transcription activator 
to promote expression of genes involved in cell cycle, but 
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also as a transcriptional repressor of genes involved in 
invasion87; MITF amplification/alteration resulting in 
dysregulation of anti-apoptotic proteins. MITF is a 
melanoma-predisposition gene because is mutated in some 
familial melanomas88. The most significant mutation in MITF 
that occurs whit higher frequency in patients affected with 
melanoma is a missense substitution (Mi-E318K). Codon 318 
is located in a small-ubiquitin-like modifier (SUMO) 
consensus site (ΨKXE) and Mi-E318K severely abolishes a 
SUMOylation of MITF inhibiting its transcriptional activity89.  
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Table 3. Common genetic alteration in melanoma 
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1.5 Theraphy 
SURGERY and ADIUVANT Theraphy 
Currently there isn’t a “gold therapy” for melanoma 
but surgical excision is considered the primary treatment for 
patient with cutaneous melanoma because renders “disease-
free” with relatively limited associated morbidity. The 
management of early-stage disease, melanoma in situ 
(margin of 0.5 cm) and low-risk primary melanomas 
(margins greater than 0.5 cm), being treated with wide 
excision and then follow-up skin exams. For patients with 
intermediate- and high-risk melanomas measuring 1.01 to 
2.0 mm in thickness wide excision is recommended. Sentinel 
lymph node mapping and biopsy is routinely offered for 
patients having 1 mm or greater deep melanomas. Also the 
patients with cutaneous melanoma metastases (Stage IIIb or 
IVa) are frequently treated with local excision followed by 
skin exams, imaging for metastases or enrollment in clinical 
trials. Cutaneous melanoma metastases can be subdivided in 
3 types:  satellite close the primary tumor (whitin 2 cm), in 
transit which are > 2 cm from the primary tumor but within 
the same region as the primary, and distant metastases far 
from the primary site90. In this patients the surgical 
approach increases their survival. It was reported a 5-year 
survival rate of 20% in 144 patients whit non-regional 
melanoma metastases91; and overall 3-4-year survival rates 
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of 36% and 31%, respectively, in stage IV melanoma 
patients92. However surgery alone cannot identify and 
address the microscopic in-transit malignant cells present 
which often give rise to future tumors. For this purpose, in 
1996 was approved high-dose interferon-alfa as adjuvant 
therapy for the stage III or IV disease. Treatment with IFN-α 
is associated with a statistically significant improvement in 
disease-free survival but not in overall survival. Moreover, 
IFN-α could cause significant toxic effects as: severe fatigue, 
depression, and hepatotoxicity93.  
Radiation therapy (RT) is used in 1–6% of patients 
with melanoma in the US in the setting of inoperable disease, 
particularly for patients in who tumor occurred pre-
dominately in the head and neck region. It is commonly used 
as adjuvant therapy or as palliative therapy to improve local 
control or in patient with desmoplastic neurotropic 
melanoma (DNM) 94. 
In the last 30 years many drugs and combination of 
drugs have introduced in melanoma therapy to improve 
patient survival for longer time. (Figure 5).  
..  
Figure 5. Timeline of FDA regulatory approval for 
metastatic melanoma. (Lo and Fisher. Science 2014) 
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CHEMIOTHERAPY 
Cytotoxic chemotherapy was the main treatment 
strategy for metastatic melanoma. Common antineoplastic 
agents currently being used include dacarbazine, 
temozolomide, high-dose interleukin-2 and paclitaxel with 
or without cisplatin or carboplatin. These have shown 
modest response rates of less than 20% in first- and second-
line settings.  
Dacarbazine [5(3,3-dimethyl-1-triazeno)-imidazole-
4-carboxamide] was the first chemotherapeutic agent 
approved by the U.S. Food and Drug Administration (FDA) in 
1970 for treatment of metastatic melanoma and it was used 
for many years. Dacarbazine is a prodrug, one of the triazene 
derivatives, that is converted in the active metabolite, 
diazomethane, by cytochrome P450.  Dacarbazine acts 
through DNA alkylation, forming crosslinks within and 
between helices that lead to local denaturation of the DNA 
strand, interfering with its form and function and killing the 
cancer cell. However, dacarbazine monotherapy is 
characterized with low overall response rates 
(approximately 10%-15%), and the drug doesn’t offer 
survival benefit. To improve response rates several 
chemotherapeutic agents as Temozolomide (a DTIC analog), 
cisplatin, carmustine, fotemustine, vinblastine, and 
tamoxifen or cytokine as interleukin-2 (IL-2) and interferon-
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alpha were added to DTIC in a variety of regimens but 
without a statistically significant survival benefit. Toxicities 
include nausea and vomiting, in over 90% of patients, 
myelosuppression (both leucopenia and thrombocytopenia) 
and flu-like illness, consisting of chills, fever, malaise, and 
myalgia95-97.  
 
IMMUNOTHERAPY 
Immunological strategies in therapy of localized and 
metastatic melanoma have a long tradition. The importance 
of immune response in melanoma derived from observation 
of the correlation between higher melanoma incidence and 
immunosuppressed patient98. Several therapies was been 
proposed for disseminated disease modulating the 
immunologic response like the nonspecific 
immunostimulant Bacillus Calmette-Guérin, interferons, 
interleukins and others but  they have failed to delivery 
major clinical benefits99-102. Also, melanoma vaccines has not 
shown significant clinical responses103.  
IL-2 
The first immune-based therapy FDA-approved for 
advanced melanoma in 1998 was IL-2, an immune cytokine 
that activates citotoxic T cell activation and promotes their 
proliferation. It stimulates, also, the development of 
lymphokine-activated killer (LAK) cells, which have the 
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ability to lyse tumor cells104-105. The use of high-dose IL-2 
showing long-term, durable complete responses in 
previously treated patients with metastatic melanoma106. 
However its use is limited by high toxicity due to 
anaphylactic shock and development of infectious 
granulomas at sites of injection and low response rates. To 
reduce systemic toxicity and increase local therapeutic 
effects, it was introduced intralesional interleukin-2 for 
treatment of cutaneous melanoma metastases, which 
showed a complete response in 78% of treated lesions107.  
Early studies showed that “tumor infiltrating lymphocytes” 
(TIL) present in tumors had potent anti-tumor activity108. So, 
adoptive cell therapies utilizing TILs in combination with IL-
2 have been promising109. Lymphodepletion prior to TIL 
infusion improve effect on adoptive cell transfer therapy 
because reduce competition for growth factors and 
cytokines in vivo microenvironment. Although 
immunotherapy with adoptive transfer of TILs is a 
promising to treat patients with refractory metastatic 
melanomas there is a technically challenging to generate 
sufficient amount of tumor-specific lymphocytes that can 
maintain their tumor-killing activity in vivo. So, it will be 
difficult to implement these therapies into routine clinical 
practice110.  
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The most successful immunotherapy approach has 
been “immune checkpoints” inhibition. This therapy is based 
on the fact that T lymphocytes are critical to antitumor 
immunity. Two of the best-studied checkpoints involve 
cytotoxic T lymphocyte antigen-4 (CTLA-4) and 
programmed cell death-1 (PD-1), two coinhibitory T cell 
receptors that mediate immune tolerance111.  
ANTI-CTLA4  
CTLA-4 is a member of the immunoglobulin 
superfamily and it is a transmembrane inhibitory receptor 
that downregulates the immune system. CTLA4 is expressed 
on the surface of T cells CD4+ and CD8+. CTLA4 is similar to 
the T-cell co-stimulatory protein, CD28, and both molecules 
bind to CD80 and CD86, also called B7-1 and B7-2 
respectively, on antigen-presenting cells. CD28 transmits a 
stimulatory signal whereas CTLA4, as a control mechanism 
around 48 hours after the initial T-cell activation, transmits 
an inhibitory signal to T cells. Intracellular CTLA4 is also 
found in regulatory T cells and may be important to their 
function112. CTLA-4 blockade with anti-CTLA-4 monoclonal 
antibodies allows appropriate T-cell activation through re-
establishment of the costimulatory binding of CD28 to B7. 
This interaction increases T-cell proliferation and amplifies 
T-cell–mediated immunity, thus, promoting the antitumor 
immune response in patients113. The first anti-CTLA-4 agent 
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to be investigated in patients with metastatic melanoma was 
Tremelimumab, a human monoclonal IgG2 anti-CTLA-4 
antibody. Although in phase I/II clinical trials, it 
demonstrated antitumor activity in patients with stage III/IV 
melanoma, a phase III study failed because tremelimumab 
shows any benefit over chemotherapy114-115. More successes 
has had Ipilimumab, a human monoclonal IgG1 anti-CTLA-4 
antibody that was approved by the FDA in 2011 for the 
treatment of patients with metastatic melanoma. In multiple 
phase III clinical trials in patients with stage III and IV 
melanoma ipilimumab monotherapy at a dose of 3 mg/kg 
bodyweight significantly improved overall survival (10.1 
months) compared to gp100 peptide vaccine monotherapy 
(6.1 months) 116. Also the treatment with ipilimumab at a 
dose of 10 mg/kg bodyweight plus dacarbazine compares 
with dacarbazine alone revealed a higher overall survival 
rate (11.2 months versus 9.1 months, respectively) with a 
28% reduction in the risk of death117. The response to 
Ipilimumab as an immunologic reaction appears slowly but 
may be long lasting. Significant immune toxicities were 
reported in this trials. Common side effects that may result 
from autoimmune reactions associated with the use of 
ipilimumab include gastrointestinal immune-related events 
(diarrhea; colitis) and other autoimmune inflammations 
(hypophysitis; thyroiditis; hepatitis) 118.  
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ANTI PD-1/PDL-1 
PD-1, like CTLA-4, is an inhibitory receptor expresses 
on T and B cells and some myeloid cells. The PD-1 ligands 
PD-L1 and PD-L2 have different expression patterns. PD-L1 
acts as a negative regulator of T cells. It is located on 
multiple normal and tumor cells like melanoma, where, once 
bound by PD-1, attenuates immune responses inducing 
peripheral tolerance to “self” antigens and, in cancer, 
promotes downregulation/termination of the immune 
response against the tumor119. PD-L2 is expressed on 
antigen-presenting cells (APC), providing tolerance to orally 
administered antigens. Humanized antibodies against both 
PDL1 and PD-1 have been developed to inhibit their 
interaction increasing antitumor activity. In clinical trials for 
many cancers, including melanoma, they have shown more 
powerful, with higher response rates and fewer autoimmune 
toxicities120-122. The human antibody nivolumab (BMS-
936558) is directed against PD-1, which in a phase I trial 
showed a responses in 28% of the melanoma patients, with 
long-term responses longer than 1 year in 50% of 
responding patients. The best response was observed with a 
dosage of 3 mg/kg bodyweight with a low rate of grade 3 or 
4 toxicity observed in only 6% of patients. Nivolumab was 
well tolerated infact were observed common side effects as 
diarrhea, rush, and pruritus123. The better safety profile of 
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PD-1 antibody versus CTLA-4 antibody is most likely due to 
the fact that it acts at tumor sites, preventing interaction 
with PD-L1 on tumor cells. A second anti-PD-1 agent, 
pembrolizumab (MK-3475, formerly known as 
lambrolizumab) is a humanized IgG4 antibody approved by 
FDA on September 2014 following phase I trial with 135 
advanced melanoma patients. It showed a response rate of 
38% in patients receiving a larger dose (10 mg/kg of 
bodyweight intravenously every 2 or 3 weeks). Most of the 
responses became evident after 12 weeks and were long 
lasting (in 81%, lasting more than 11 months). Adverse drug 
reactions, reported in 79% of patients, included fever, chills, 
fatigue, rash and pruritus124. An anti-PD-L1 human IgG4 
antibody (BMS- 936559) is being tested in phase I trial in 55 
patients with melanoma. Preliminary results showed 
significant tumor long-term response of 29% with the dose 3 
mg/kg bodyweight and a comparable rate of grade 3 or 4 
adverse effects125. Other two anti-PD-L1 antibodies, 
MPDL3280A (Genentech) and MEDI4736 (MedImmune), are 
being tested in solid tumors under early phase clinical trials. 
Recent preliminary results of MDPL3280A trial showed an 
overall response rate of 29% in 44 patients with melanomas 
of different origins126. Combination therapies utilizing 
multiple immune modulating agents that block of both 
immune checkpoints (PD-1 and CTLA4) are showing great 
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promise. Anti-PD-1/nivolumab/MK-3475 and anti-CTLA-
4/Yervoy antibodies are being combined in clinical trials 
(NCT01024231). This treatment produced an objective 
response rate of 40% in 52 patients at a variety of dose 
levels and in several patients tumors disappeared 
completely127.  
 
TARGET THERAPY 
Concurrent advances in targeted molecular therapy 
have also improved the treatment and prognosis of a subset 
of advanced melanoma patients. Approval of single 
substances directed against mutated proteins has 
dramatically changed the options available in melanoma 
therapy. 
 
BRAF inhibitors  
BRAF-targeted therapies represent the first major 
breakthrough in systemic therapy for metastatic melanoma. 
The earlier BRAF inhibitor is nonselective multikinase 
inhibitor sorafenib (BAY 43-9006). It acts as a pan-inhibitor 
of RAF, which targets not only BRAF but also CRAF as well as 
the vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF) receptor tyrosine kinases 
(RTKs) 128. However, sorafenib did not show great benefit, in 
clinical trials neither as monotherapy or in combination with 
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other anticancer compounds, such as dacarbazine, 
carboplatin and paclitaxel in patients with metastatic 
melanoma129. The latest generation of highly specific and 
potent BRAF inhibitors offers a significant improvement 
over sorafenib against mutant BRAF. These drugs show a 
greater selectivity for mutant BRAF and have fewer off-
target effects. The first selective BRAF inhibitor targeting the 
mutant V600E form is PLX4720 (vemurafenib). 
Vemurafenib is a potent ATP-competitive RAF 
inhibitor that co-crystallizes with a protein construct 
containing the kinase domain of BRAF V600E to enable 
preferential binding to the ATP-binding domain of mutant 
BRAF130. Pre-clinical studies showed that vemurafenib 
inhibits the kinase activity of BRAF harboring the V600E 
mutation with an half maximal inhibitory concentration 
(IC50) of 13 nM, resulting in selectively blocked the 
RAF/MEK/ERK pathway and consequent cell-cycle arrest 
and the induction of apoptosis in melanoma cells131. In 2011 
vemurafenib/Zelboraf (960 mg twice daily) received FDA 
approval for treatment of metastatic or unresectable 
melanoma harbouring the BRAF mutation V600E following 
the results of a phase III trial, BRIM-3.  The 675 enrolled 
patients, previously untreated, with BRAF V600E mutation-
positive metastatic melanoma were randomized to receive 
vemurafenib at 960 mg orally twice daily, or dacarbazine 
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chemotherapy of 1,000 mg/m2 intravenously every three 
weeks. The six-month overall survival was 84% in the 
vemurafenib arm and 64% in the dacarbazine arm. Many 
patients treated with vemurafenib had a rapid tumor 
response with resultant decreased tumor weight as 
indicated by the high overall response rate that was 48% for 
vemurafenib compared to 5.5% for dacarbazine132. 
Vemurafenib is not truly selective for BRAF mutant 
melanoma cells and can paradoxically activate the MAPK 
pathway in wild-type BRAF cells133 which resulting in 
several toxicities, concerning frequency and intensity during 
treatment,  as the development of a rash, in some associated 
with a severe photosensitivity (UVA), arthralgia, 
keratinocytic neoplasia  and squamous cell carcinoma134.  
The second BRAF inhibitor that has been approved 
for the treatment of BRAF V600 mutated metastatic 
melanoma by the FDA on May 30th 2013 is dabrafenib. 
Dabrafenib/Tafinlar is a specific inhibitors of BRAF 
V600E/K. In a phase III clinical trial (BREAK-3), dabrafenib 
(150 mg twice daily) was compared with dacarbazine in 
previously untreated patients with advanced melanoma 
with mutated BRAF. As vemurafenib dabrafenib showed 
significant high response rates and reduced of 70% in risk 
for disease progression versus standard therapy135. Toxic 
side-effects included skin lesions, pyrexia, frequent fatigue, 
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nausea and pain. The development of photosensitivity and 
epithelial tumors were less frequent than vemurafenib. 
Other BRAF inhibitors that are currently being 
evaluated in clinical trials are LGX818, BMS-908662, XL281 
ARQ736, and RAF265 (clinicaltrials.gov). In particular, 
LGX818 is in a phase I trial and has shown the similar 
response rates (58%) but lower toxicity than vemurafenib 
and dabrafenib136. New inhibitors are in development to 
eliminate the side effects associated with the paradoxical 
activation by vemurafenib of the ERK1/2 pathway in wild-
type BRAF cells. PLX7904, a new “paradox-breaking” BRAF 
inhibitor, that inhibits MAPK signaling in BRAF-mutant cells 
without activating BRAF in BRAF wild-type cells137.  
A major problem with the use of these inhibitors and 
the further advancement of melanoma therapies is de novo 
or acquired drug resistance. Infact, unfortunately, some 
patients with BRAF-mutated melanoma do not respond to 
therapy or show tumours progress or grow again with a 
median time to progression of approximately 6-8 months138. 
Primary or de novo resistance may be due to pre-existing 
mutations (intrinsic) or interactions between tumor cells 
and microenvironments (extrinsic). Further additional 
mutations in the MAPK pathway (eg. MEK2) and in the PIK3 
pathway (eg. PIK3 and AKT1), or loss of NF1 function (which 
regulates RAS) have been shown to escape the effects of 
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BRAF (and MEK) inhibitors activating bypass survival 
pathways, in particular, PI3K/AKT pathway139-141. Secondary 
or acquired resistance to BRAF inhibitors, when melanomas 
begin to grow again following an initial successful treatment, 
occurs inevitably in most of the patients treated. The 
secondary resistance to BRAF inhibitor was mainly 
associated to several MAPK pathway -dependent or -
independent mechanisms. Acquisition of new mutations in 
NRAS or the downstream kinase MEK1, BRAF amplification 
or splicing, overexpression of cancer osaka thyroid (COT), 
and activation of RTKs cause rapid regrowth of existing 
metastases or the emergence of new142-145. Although the 
resistance mechanisms identified so far are diverse, most 
appear correlate to reactivation of MEK/ERK signaling and 
increased of the PI3K/AKT/mTOR pathway. Moreover, cell 
growth and proliferation are controlled by a network of 
pathways consisting of various key proteins which might be 
mutated, so the block of a single checkpoint will not be 
successful in the long-term. Correspondingly, to overcome 
the impact of resistance to BRAF inhibitors, the designed 
drug combination may provide a more durable response 
rate and may prolong progression-free survival (PFS) in 
patients with BRAF mutant melanoma, compared with either 
agent alone. The most promising combination strategy is the 
simultaneous inhibition of BRAF, MEK and PI3K pathway146-
48 
147. Another interesting strategy being investigated in clinical 
trials that may help overcome BRAF inhibition resistance is 
the use of intermittent dosing of vemurafenib after the 
maximum response to therapy to prolong the response 
duration148. A better understanding of the molecular biology 
of melanoma has helped the development of new therapies.  
 
MEK inhibitors  
There are two major classes of MEK inhibitors, ATP 
non-competitive and ATP competitive inhibitors. Currently, 
most MEK inhibitors are non-competitive, indicating that 
they do not compete for the ATPbinding site and instead 
bind to an adjacent allosteric site, which explains their high 
specificity149. MEK is a downstream kinases of BRAF so its 
inhibition leads to decreased cell signalling and proliferation 
in cancer cells inducing apoptosis150. Trametinib/Mekinist 
(GSK1120212) is a non-competitive MEK1/2 inhibitor and it 
was FDA-approved in 2013 for the treatment of adult 
patients with the BRAF V600E/K mutation and unresectable 
or metastatic melanoma at the dose of 2 mg orally once 
daily151. Inhibition of MEK has been explored in clinical trials 
for melanoma patients with mutant BRAF. In a phase III 
randomized trial trametinib compared to chemotherapy 
(dacarbazin or paclitaxel) showed a marked improvement in 
both progression free and overall survival (respectively 4.8 
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months and 81% vs 1.5 months and 67%) 152. The adverse 
effects is mild, including rash, cardiac dysfunction, ocular 
toxicities, diarrhea, peripheral edema, and hypertension 
which could be managed with dose reduction or 
interruption. Currently, several MEK inhibitors have showed 
efficacy in the treatment of  melanoma as selumetinib and 
MEK162, while other are in clinical development as PD-
0325901, refametinib, RO-4987655, TAK-733, and XL518. 
Recently, MEK162 monotherapy revealed a response rate of 
21% in NRAS-mutated melanoma153-154. Patients who did 
not respond to vemurafenib or who have develop resistance 
to BRAF inhibitor usually will not benefit from MEK inhibitor 
monotherapy because the mechanisms involved in 
development of resistance to mutant BRAF confer resistance 
to MEK inhibition.  
MEK and BRAF combined therapy 
Numerous preclinical and clinical studies have shown 
that the combination of BRAF and MEK inhibitors is a 
successful strategy for the treatment of metastatic 
melanoma. Preclinical studies have demonstrate that this co-
inhibition reduces tumor growth, increases apoptosis and 
delays the onset of resistance when compared with 
monotherapy155. The first combination to be tested in 
clinical trials was the BRAF inhibitor dabrafenib with the 
MEK inhibitor trametinib. In a phase II trial, in 54 MAPK 
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inhibitor-naive patients with BRAFV600E/K mutation, the 
CombiDT (dabrafenib 150 mg twice daily and trametinib 2 
mg daily) showed promising activity in patients with stages 
III or IV melanoma and fewer side effects compared with 
vemurafenib. They induce a significantly higher response of 
76% vs 54% for dabrafenib alone and an evident 
improvement in PFS (9.4 months in the combination group 
vs 5.8 months in the monotherapy group). No patient 
recorded progressive disease as their best response146; 156.  
The CombiDT showed, also, less toxicities than dabrafenib 
alone. Infact, the addition of trametinib reduced the 
appearance of cutaneous squamous cell carcinomas146. The 
most common toxicity was pyrexia, which occurred in 71% 
of patients (5% had grade 3 or 4 reactions). On the basis of 
these results FDA has granted accelerated approval of the 
combination of dabrafenib and trametinib for the treatment 
of patients with metastatic melanomas that carry the 
BRAFV600E or BRAFV600K mutation in January 2014. A 
phase III clinical trial comparing the combination of 
dabrafenib and trametinib with dabrafenib alone 
(NCT01584648) and dabrafenib and trametinib with 
vemurafenib monotherapy (NCT01597908) is also in 
progress. Other BRAF and MEK inhibitor combinations have 
also shown promise and are in phase III trials as 
vemurafenib and cobimetinib (CombiVC) 
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(NCT01689519)157; and LGX818 and MEK162 
(NCT01909453)158. Unfortunately, it has been shown that 
the response to Combi therapy after disease progression 
with BRAF inhibitors has little efficacy. Moreover, a dual 
BRAF/MEK inhibitor, RO5126766, has recently shown 
activity in patients with metastatic melanoma, suggesting 
that combined inhibition of BRAF and MEK will be of the 
gratest benefit for metastatic melanoma patients159. 
However, about 50% of individual metastases have a 
complete response but most patients still relapse within a 
year although rarely resistance emerges in the lesions that 
had a complete response146. Other early-phase combination 
trials with approved BRAF inhibitors explore addition of 
inhibitors of PI3K, AKT, CDK, HSP90, RTKs and other targets, 
as well as immunotherapy, to improve durability of 
responses. 
ERK inhibitors 
ERK1/2 are the kinases below MEK in the MAPK 
cascade, they are the primary effector of this pathway, and 
regulates the activity and expression of transcription factors 
and proteins that result in cell growth, proliferation, and cell 
cycle progression. Most BRAF inhibitor resistance (and 
combination BRAF and MEK inhibitor resistance so far) 
results in reactivation of ERK signalling. Thus, inhibition of 
ERK might represent an emerging therapeutic strategy for 
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the treatment of BRAF inhibitor-resistant melanoma. 
Preclinical evidence suggests that ERK inhibition is effective 
in BRAF inhibitor-resistant melanoma with common MAPK-
reactivating resistance drivers (RAS, MEK1 mutations, BRAF 
splice variants, and BRAF amplifi cation). Several candidate 
drugs are in phase I trials, as MK-8353 (NCT01358331)160-
161. 
KIT inhibitors  
C-KIT is a receptor tyrosine kinase that when binding 
to its ligand activates the MAPK, PI3K/AKT and Janus 
Kinase/Signal Transducer and Activator of Transcription 
(JAK/STAT) signaling pathways, resulting in proliferative 
and survival effects162. Selective inhibitors of KIT (imatinib; 
sunitinib; nilotinib; dasatinib) which were developed and 
used for the treatment of other types of cancer (such as 
gastrointestinal stroma tumor [GIST] or chronic myeloid 
leukemia) became interesting also for melanoma 
treatment163. In a phase II trial using imatinib (400 mg orally 
once-daily), in selected melanomas (acral; mucosal; sun-
damaged skin), the best overall response rate was  77% in 
cases with KIT mutation compared to only 18% in cases with 
KIT amplification164. Imatinib was well tolerated and didn’t 
show very serious adverse effects at utilized dose. On the 
basis of these data, imatinib has shown promising results as 
a therapeutic agent in patients with metastatic melanoma 
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and mutations in the KIT gene. Other tyrosine kinase 
inhibitors (sunitinib, dasatinib, and nilotinib) are underway 
a phase III trials. The major limitation of this study has been 
the rarity of mutations in this gene, which occur in less than 
5% of patients with melanoma165.  
 
NRAS inhibitors 
Neuroblastoma RAS viral oncogene homolog (NRAS) 
is mutated in approximately 15% to 20% of melanoma and 
seems to correlate with a worse prognosis compared to 
NRAS/BRAF wild-type patients166. Developing drugs 
targeting mutated NRAS is challenging because multiply 
pathways are unregulated due to this mutation. Infact, 
current drug development focuses on targeting the 
downstream effectors of NRAS, the MAPK and PI3K 
pathways. MEK162 is the most promising MEK inhibitor, 
showing response in 20% of the patients with NRAS-
mutated melanoma167. It is most likely that such patients will 
benefit much more from the combination therapies and a 
trial (NCT01781572) that combining MEK162 and LEE011, a 
cyclin-dependent kinase (CDK) 4/6 inhibitor, in patients 
with NRAS-mutated melanoma is ongoing. 
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PI3K/AKT inhibitors 
The PI3K/AKT pathway regulates several cellular 
processes including proliferation, survival, motility, 
metabolism, and angiogenesis. This pathway is activated by 
receptor tyrosine kinases and RAS proteins and is inhibited 
by PTEN. Alterations in the PI3K pathway have also been 
reported in 60% of the melanomas168-169. Several classes of 
PI3K pathway inhibitors exist including PI3K inhibitors, AKT 
inhibitors, mTOR inhibitor, dual PI3K\mTOR inhibitor and 
dual mTOR1\2 inhibitor that down-regulate the activation of 
this survival pathway. The first generation of inhibitors of 
PI3K signaling in melanoma was rapamycin and the second-
generation agents were everolimus (RAD001) and 
temsirolimus (CCI-779), they allosterically inhibit the 
mTORC1 complex170-171. These agents have long been used 
as immunosuppressor in patients with organ transplants 
and have demonstrated anti-proliferative effects against 
many human cancers172. However, clinical trials in 
melanoma have shown a lack of objective responses to 
mTORC1 inhibitors as single agents or in combination with 
BRAF inhibitors173-174. The reason for this seems to be 
interruption of negative feedback loops mediated by 
mTORC1, causing activation of PI3K, AKT and ERK175. 
mTOR complex-1 inhibitors are now in use in a 
multitude of cancer types. Dermatologic side effects are 
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common and include stomatitis, eruptions, and nail changes, 
including paronychia. Few data are available about the 
pharmacodynamics effects of PI3K and AKT inhibitors in 
patient. Most of them are now under clinical trials in 
melanoma (both wild-type and BRAF mutant), often in 
combination with MAPK inhibitors (clinicaltrials.gov; 
NCT01820364; NCT01616199; NCT01337765; 
NCT01941927; NCT01166126; NCT01014351; 
NCT00022464). 
 
CDK4 and CDK6 inhibitors 
The CDK4-CDK6 pathway sits below the MAPK 
pathway and involves p16, cyclin D, CDK4 and CDK6, and the 
RB1 protein. This pathway is aberrantly activated in most 
melanomas resulting in increased cell cycle progression, 
reduced induction of apoptosis, and cell senescence176-177. 
Inhibitors of CDK4, such as palbociclib (PD0332991; 
NCT01037790), SCH 727965 (dinaciclib), LY2835219, 
BAY1000394, LEE011), and the combination of LGX818 with 
LEE011 (NCT01777776), are currently in clinical trials for 
various advanced cancers including melanoma. 
Other targets  
Several other targets exist in BRAF-mutant 
melanoma, ranging from growth factors in the tumour 
microenvironment (eg, HGF and VEGF), receptor tyrosine 
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kinases at the cell surface (eg, MET, FGFR, and VEGFR), 
epigenetic regulators (eg, histone deacetylase), and 
apoptosis regulators (eg, MDM2). Lapatinib, an Epidermal 
Growth Factor Receptor/Human Epidermal growth factor 
Receptor 2 (EGFR/HER2) inhibitor, showed activity in cell 
lines harboring ERBB4 mutations and not in ERBB4 wild-
type cells. Mutations in ERBB4 observed in 19% of patients 
with melanoma can cause an overactivation of the ERK and 
AKT pathways. Currently, a phase II trial testing lapatinib in 
patients with advanced melanoma with ERBB4 mutations is 
ongoing (clinicalltrials.gov; NCT012 64081)178.  
 
Figure 6. Cell signalling pathways and drug targets 
(Menzies and Long, Lancet Oncol. 2014) 
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2. Hydrogen Sulphide 
2.1 Physical and Chemical Properties of H2S 
Over millions of years hydrogen sulphide (H2S) 
caused life destructions and extinctions on the earth. Is 
believed that in Permian period H2S provoked a mass 
extinctions on earth, than the emissions from massive 
volcanic eruptions in Siberia caused a chain reaction of 
environmental events that resulted in oxygen depletion in 
the world’s oceans and, therefore, the died of many species 
that leved there. Otherwyse, some non-oxygen (anaerobic) 
breathing organisms called green sulfur bacteria 
(Chlorobium) continued to grow and reproduce at high 
rates. These green sulfur bacteria used sulfate dissolved in 
water for respiration instead of oxygen, and subsequently 
produced H2S. According to this theoretical perspective the 
large amounts of H2S produced by these organisms created 
so much lethal gas in the ocean that it then diffused into the 
air and land destroyed the plant and animal life as well. By 
the end of the Permian period, 95% of marine species and 
70% of terrestrial ones had vanished179. Actually a great 
diversity of microorganisms, bacteria, fungi as well as plants, 
are be able to produce H2S180-181. Interestingly, plants are the 
primary producers of organic sulfur compounds and are able 
to couple photosynthesis to the reduction of sulfate, 
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assimilation into cysteine, and further metabolism into 
methionine, glutathione, and many other compounds. 
Animals, instead, have a dietary requirement for sulfur 
amino acids. Cysteine is the central intermediate from which 
most sulfur compounds are synthesized182.  
H2S, along with nitric oxide (NO) and carbon 
monoxide (CO), forms part of a group of biologically active 
gases that are termed gasotransmitters or gasomediators. 
H2S is a colorless, water-soluble and flammable gas with an 
unpleasant smell of rotten eggs. H2S is the predominant 
sulphur contaminant of natural gas and ranges in 
concentration from <1 to >90%. 
H2S has a molecular weight of 34.08 and its chemical 
structure is analogue to that of water molecule with an atom 
of sulfur being less electronegative than the first and much 
less polar (Figure 7). Infact, H2S has a vapor density (d) of 
1.19, heavier than air (d=1.0), boiling point (-60.7 °C) and 
melting point (-82.3°C) is much lower than they are in water 
and freezing point is -86°C.  
 
 
Figure 7. Similarity in molecular structure between water 
(H2O) and hydrogen sulfide (H2S). 
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H2S is a weakly acidic, dissociating in aqueous 
solution into hydrogen cation (H+) and hydrosulfide anion 
(HS-) (Ka1= 1.3*10-7 M), which subsequently may decompose 
to H+ and sulfide anion (S2-) (Ka2= 1*10-19 M) in the following 
reaction183-185:        
                         Hydrogen Sulfide Dissociation 
 
Under physiological conditions, at 37°C and pH 7.4, equal 
amounts of H2S and HS- are within the cell, and 
approximately a 20% H2S/80% HS- ratio in extracellular 
fluid and plasma. Conversely, the chemical form S2- is not 
present in appreciable amounts, since the dissociation of HS- 
occurs only at high pH values. 
H2S present in the air comes from organic and inorganic 
sources. Organic sources include bacteria and 
decomposition of matters such as released from septic tanks, 
sewers, or water treatment plants, while inorganic sources 
are natural gas, petroleum refinery, rayon manufacturing, 
paper and pulp mill industry, sulfur deposits, volcanic gases, 
and sulphur springs. The half-life of H2S in air varies from 12 
to 37 h. The temperature would change the half-life and the 
solubility of H2S. H2S is a highly lipophilic molecule, such as 
it can easily penetrates lipid bilayer of cell membranes.  
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The toxic effects of this small molecule were known long before 
its physiological properties. Back to World War One, H2S was 
used by the British as a chemical agent. It has been postulated 
that H2S exerts dose-dependent toxicity with millimolar 
concentrations. Accumulation of H2S gas in confined or closed 
spaces, including septic tanks and cesspools, animal processing 
plants, pump mills, and sludge plants has been the cause of 
numerous cases of human deaths. Sudden release of H2S gas in a 
huge amount from oil wells or refineries leads to infamous 
“knock-down” phenomenon of oilers and other petrochemical 
workers, an instant loss of consciousness often associated with 
respiratory failure
186-188
. Most organ system are susceptible to 
the effects of H2S and each system exhibits a different response 
according as a concentration, time or rate of exposure. The 
lethal concentration for 50% of humans for 5 min exposure 
(LC50) is 800 ppm, and concentrations over 1,000 ppm cause 
immediate collapse with loss of breathing, with only a single 
inhalation needed. Tissues most susceptible to H2S toxicity are 
those with exposed mucous membranes and those with high 
oxygen demands
189
. This gas is considered a broad-spectrum 
poison to humans in the nervous system, respiratory system, and 
cardiovascular system; infact, at concentrations <1000ppm, can 
have toxic effects that occur with eye irritation, sore throat, 
dizziness, nausea, difficulty breathing and chest stiffness; at 
concentrations >1000ppm, it can cause serious adverse effects 
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resulting in respiratory paralysis, pulmonary edema, cardiac 
arrhythmias, stroke and death. 
The molecular mechanisms underlying the toxicological 
effects of H2S are mostly attributed to its ability to induce K (+)-
channel-mediated hyperpolarization of neurons and potentiation 
of other inhibitory mechanisms, or to inhibit cytocrome c 
oxidase in mitochondria, at micromolar concentrations, reducing 
ATP production
190
. However, over the last decade it has 
become clear that it is not only detectable in significant 
amounts in mammals, including humans, where it appeared 
in blood from nanomolar to micromolar concentration 
range, but that it is also produced endogenously and may 
play a significant role in both normal physiology and the 
pathophysiology of disease. 
 
2.2 Endogenous Production of H2S in 
mammalian cells 
Enzymatic Production of H2S 
In mammals, H2S is endogenously produced by 
enzymatic reactions and by nonenzymatic pathways. The 
key precursors for endogenous H2S synthesis are sulfur-
containing amino acids as L-cysteine, that derives from 
alimentary sources, or synthesizes from L-methionine, 
through the so-called “trans-sulfuration pathway” with 
homocysteine (Hcy) as an intermediate, or liberates from 
endogenous protein. H2S is generated by four separate 
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enzymes that are cystathionine gamma-lyase (CSE, EC 
4.4.1.1), cystathionine beta-synthase (CBS, EC4.2.1.22), 
cysteine aminotransferase (CAT, EC 2.6.1.3) and 3-
mercaptopyruvate sulfurtransferase (3-MST EC 2.8.1.2)191 
(Figure 8).  
Interestingly, these enzymes are evolutionarily conserved 
and occur in many lower species as well as in mammals and 
their expression is tissue-specific192. CBS is the predominant 
enzyme responsible for H2S generation in the brain and the 
nervous system, and is also highly expressed in the liver and 
kidney193. CSE is expressed abundantly in mammalian 
cardiovascular system and respiratory system. It also 
appears to be the main H2S-forming enzyme in the liver, 
kidney, uterus, placenta, smooth muscle as well as 
pancreatic islets194-195. 3-MST can be found in proximal 
tubular epithelium in the kidney, pericentral hepatocytes in 
the liver, cardiac cells in the heart and neuroglial cells in the 
brain196. Both CSE and CBS are expressed in the human colon 
in the myenteric plexus neurons, and evidence indicates that 
human colonic mucosa metabolizes L-cysteine to H2S197. 
Importantly, while CBS and CSE are hemeproteins primarily 
located in the cytosol, 3-MST is a zinc-dependent protein 
found in both the mitochondria and cytosol. CBS and CSE are 
pyridoxal 5’-phosphate (PLP) dependent enzymes and they 
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are responsible for the majority of the endogenous 
production of H2S in mammalian tissues. 
CBS is a cystathionine-forming enzyme and it 
catalyzes β-replacement reactions between L-serine, L-
cysteine, cysteine thioethers, or some other β-substituted -
L-amino acids, and a variety of mercaptans. Homocysteine is 
the physiological substrate for CBS and in presence of 
cysteine their condensation generate, as final products, 
cystathionine and H2S198. In addition to H2S production, CBS 
has a prominent role in maintaining homocysteine levels in 
vivo. Patients with homocysteinaemia exhibit impaired CBS 
activity, due to mutations of the regulatory domain of CBS, 
and display markedly increased levels of homocysteine and 
low H2S levels that contribute to the cardiovascular 
disease199-200. Human CBS is a homotetramer consisting of 
63 kDa subunits which bind two cofactors, PLP and heme. 
Each CBS subunit of 551 amino acid residues binds two 
substrates (homocysteine and serine). The NH2 terminal of 
CBS contains the binding sites for both PLP and heme 
(protoporphyrin IX). Although, there is no clear a role of 
heme in the catalytic activity of CBS, seems to be redox 
sensor because its deletion renders CBS insensitive to 
oxidative stress201. The PLP binding domain is the catalytic 
domain, and it is deep in the heme domain, linked by a Schiff 
base. The COOH terminal of CBS contains a regulatory 
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domain of 140 residues, playing an autoinhibitory role for 
the activity of full-length CBS. Binding of the allosteric 
activator, S-adenosyl-L-methionine (AdoMet or SAM), to this 
domain will cause a conformational change so that CBS is 
instantly activated. Deletion of the regulatory domain 
constitutively activates CBS202. The activity of CBS is, also, 
regulated at the transcriptional level by glucocorticoids and 
cyclic AMP. The activity of CBS can be directly inhibited by 
nitric oxide (NO) and carbon monoxide (CO) 203. 
CSE has been described as an exclusively beta-
replacing lyase with a strict specificity for the primary 
substrate L-cysteine and for several sulfur-containing 
cosubstrates. It catalyses a β-disulphide elimination reaction 
that results in the production of thiocysteine, pyruvate, and 
NH4+ from cystathionine. Thiocysteine may react with 
cysteine or other thiols to form H2S. CSE is able to convert, 
also, directly L-cysteine in pyruvate, NH3 and H2S and L-
homoserine in H2O, NH3, and 2-oxobutanoate (o -
ketobutyrate) 204. Rat CSE (but not human CSE) may also use 
cystine, the disulfide form of Cys, as a substrate to generate H2S 
in the presence of a reductant
205
. The concentration of cystine in 
the reducing environment of cells is extremely low, so it is 
unlikely that cystine contributes to H2S biogenesis under normal 
conditions. CSE seems to be the dominant enzyme for the 
formation of H2S in mammalian tissues as demonstrates by 
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CSE-KO mice that exhibit a profound depletion of H2S in 
peripheral tissues
206
. Human deficiency of CSE may lead to 
cystathioninuria, a metabolic disorder characterized by an 
excess of cystathionine in the urine that is inherited in an 
autosomal recessive manner.  Other diseases related to CSE 
mutation include hypercystathioninemia and increase the 
risk of developing atherosclerosis and bladder cancer207. CSE 
is a protein of 405aa and is a tetramer formed by two 
homodimers, both contributing to the active site pocket. 
There are two isoforms of human CSE as the consequence of 
alternative splicing208. Activity of CSE is regulated at 
transcriptional level by myeloid zinc finger 1 (MZF1) and 
specificity protein 1 (SP1; also known as Sp1 transcription 
factor), and the enzyme can be upregulated by bacterial 
endotoxin209. A recent study has reported the crystal 
structures of human CSE (hCSE), in apo form (apo-hCSE), 
complexed with PLP (hCSE·PLP) and with the inhibitor DL-
propargylglycine (PAG) (hCSE·PLP·PAG). The structure of 
hCSE·PLP·PAG complex highlights the particular importance 
of Tyr114 in hCSE and the mechanism of PAG-dependent 
inhibition of hCSE210.  
In mitochondria 3-MST produces H2S through a 
reaction involving the generation of pyruvate from 3-
mercaptopyruvate (3-MP). It also catalyse the 
transsulfuration of a thiol to a persulfide, which can 
66 
subsequently join a second thiol to form a disulfide and 
release H2S. 3-MP is provided through the reaction of 
cysteine and α-chetoacid (e.g. α-ketoglutarato) by CAT. In 
the cytosol, the thiocysteine formed by cystathionase can act 
as an acceptor of the sulfur transferred from 3-
mercaptopyruvate by MST211.  
Non-enzymatic Production of H2S 
Non-enzymatic production of H2S occurs through 
glucose, glutathione, inorganic and organic polysulfides and 
elemental sulfur. H2S can be generated from glucose via 
glycolysis or from phosphogluconate via NADPH oxidase. 
Glucose reacts with methionine, homocysteine or cysteine to 
produce gaseous sulfur compounds. H2S is also produced 
through direct reduction of glutathione and elemental 
sulphur that is mediated by NADH or NADPH. Increased 
oxidative stress and hyperglycemia will promote H2S 
production from this path212. The enterobacterial flora is an 
important source of H2S. The intestinal epithelium expresses 
specialized enzyme namely sulfate-reducing bacteria (SRB) 
that efficiently degrade sulphide to thiosulphate and 
sulphate to protect itself against high local concentrations of 
sulphide and to prevent an excessive entry of H2S into the 
systemic circulation213. H2S can also be released from 
thiosulfate and persulfides. Garlic and garlic-derived organic 
polysulfides induce H2S production in a thiol-dependent 
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manner. H2S is excreted in the urine primarily as sulfate 
(either free sulphate or thiosulfate) and in feces and flatus as 
free sulfide. 
 
 
Figure 8. The biosynthesis of hydrogen sulfide in 
mammalian cells. (Kolluru et al., Nitric Oxide, 2013) 
 
 
Catabolism of H2S  
The main catabolic pathways of H2S are represented 
by oxidation and methylation (Figure 9). Much of the 
inactivation of H2S occurs via mitochondrial oxidation. Two 
membrane-bound sulphide, quinone oxidoreductases (SQR), 
oxidize sulfide to elemental sulfur and reduce their cysteine 
disulfides. Then, sulfur dioxygenase (SDO) oxidizes one of 
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the persulfides to sulfite (H2SO3). Sulfur from the second 
persulfide is transferred from the SQR to sulfite by sulfur 
transferase (ST) producing thiosulfate (H2S2O3). Thiosulfate 
is, subsequently, converted in sulfite (SO32-) and sulphate 
(SO42-), by thiosulfate reductase and sulfite oxidase or is 
conjugated with cyanide ions (CN-) to generate thiocyanic 
acid by rhodanase enzyme (RHOD; also known as thiosulfate 
cyanide sulfurtransferase, TST). Also, sulfite originating 
through this reaction is quickly oxidized to sulfate, the major 
end-product of H2S metabolism under physiological 
conditions214. For every mole of H2S oxidized 1.5 mole of 
oxygen is consumed along the electron transport chain. 
Metabolism of H2S through SQR appears ubiquitous in all 
tissues except the brain215. This process maintains very low 
intracellular H2S concentrations. In cytosol and in the 
gastrointestinal tract, H2S is catalyse mainly by thiol-S-
methyltransferase (TSMT) that converts sulfide to 
methanethiol (CH3SH), which is less toxic to colonocytes 
than sulphides, by methylation. These enzymes are 
presumed to have a protective function, preventing 
excessively high local concentrations of sulfide and H2S 
entry into the systemic circulation216-217. 
Methemoglobin, considered a “common sink” for 
endogenous gases including CO and NO, also binds H2S to 
form sulfhemoglobin. Therefore, the half-life of free H2S in 
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blood may also be short218. It was demonstrated that 
pretreating wild-type HEK-293 cells with methemoglobin for 
1 h prior to adding 100µM H2S significantly abolished the 
antiproliferative effect of H2S219. H2S can also be scavenged 
by metallo- or disulfide-containing molecules such as 
horseradish peroxidise, catalase, and oxidized 
glutathione220. 
 
 
 
Figure 9. Catabolism of H2S (Kolluru et al., Nitric Oxide, 
2013) 
 
 
 
2.3 Molecular targets of H2S  
Once produced in mammalian cells, H2S can directly 
exert its biological effects via interaction with different 
signalling molecules or can store as sulfur and released later in 
response to a physiological signal (Figure 10). Acid-labile sulfur 
and sulfane sulphur are the two main forms of sulfur stores in 
mammalian cells
221
.  
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In the cells H2S exists in equilibrium with its anionic 
form HS
−
, (ratio 1:4). As a gasotransmitter, H2S does not use a 
specific transporter, and its lipophilic nature allows it to rapidly 
travel through cell membranes
222
, whereas HS
−
 anions cannot 
cross cell membranes and therefore might only target 
intracellular proteins. Recently was identified a channel 
permeable to HS
−
 anions in the bacterium Clostridium 
difficile
223
. The best mode of H2S signalling is through protein 
sulfhydration, which occurs at reactive Cys residues of target 
proteins. In this process, the sulfhydryl group of a reactive 
Cys is modified to a -SSH group, resulting in increased 
reactivity of the Cys residue. The regulation machineries for 
S-sulfhydration depend by ATP level, pH value, ionic 
strength, and oxygen partial pressure224. The first reported 
molecular target for H2S was the ATP-sensitive potassium 
channels (KATP) which activation accounts in numerous 
distinct pharmacological effect of H2S194. The stimulatory 
effect of H2S on KATP channel complex relied on a direct 
interaction between H2S molecule and the disulphide bond 
on the extracelluar loop of the SUR1 subunit of KATP 
channels225. A direct confirmation of the effect of this gas on 
the KATP channel has come from electrophysiological studies 
in which NaHS increased the KATP current in rat aortic and 
mesenteric smooth muscle cells. H2S is also known to act on 
a number of other ion channels. H2S inhibits BKCa (big 
conductance Ca2+-sensitive K+) channels in stably 
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transfected HEK-293 cells226, whereas the opposite effect 
was noted in rat pituitary tumor cells227; inhibits L-type Ca2+ 
channels in cardiomyocytes228; T-type Ca2+ channels 
mediating visceral pain in the mouse229 and intracellular 
chloride Cl- channels in rat heart lysosomal vesicles230; it 
activates transient receptor potential vanilloid (TRPV) 
channels in both urinary tract231 and airway smooth 
muscle232. Important targets of H2S are the intracellular 
transcription factors. The first evidence was done by Oh and 
colleagues that demonstrated NaHS reduce LPS-induced NF-
κB activation in cultured RAW 264.7 macrophages inhibiting 
IκB-α degradation and NF-κB nuclear translocation233. As 
NaHS, many H2S donors, like GYY4137, S-diclofenac, garlic 
compounds such as diallyl sulfide (DAS), can also 
downregulate NF-κB activation234-236. The functional 
consequence of reduced NF-κB activation in inflammatory 
cells is downregulation of a number of proinflammatory 
genes, including those that encode for inducible nitric oxide 
synthase (iNOS) and cyclooxygenase-2 (COX-2), as well as 
downregulation of inflammatory cytokines/chemokines and 
adhesion molecules.  
However, under some experimental circumstances, 
NaHS can be proinflammatory and can augment (not inhibit) 
IκB-α degradation and thence increase (not reduce) NF-κB 
activation237. Moreover, recently, was established that H2S 
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synthesized by CSE, than TNF-α stimulation, is able to 
sulfhydrate the p65 subunit of NF-κB at cysteine-38, 
enhancing its binding to the co-activator RPS3, thereby 
augmenting the transcription of several anti-apoptotic 
genes238. Clearly, there is considerable variation in the way 
that the NF-κB system responds to H2S that depends on the 
cell type and/or culture conditions used during the studies 
and, also, on the precise stage of the inflammatory response. 
Infact NF-κB has a proinflammatory role in the early stages 
of inflammation and anti-inflammatory role in the resolution 
phase. Additional transcription factors are also targets for 
H2S. The signal transducer and activator of transcription 3 
(STAT3), that regulate the expression of many genes that 
mediate cell survival (e.g., survivin), proliferation (e.g., c-
fos), and angiogenesis (e.g., vascular endothelial growth 
factor), results activated by H2S239. NaHS also induces the 
nuclear localization of the transcription factor NF-E2-related 
factor 2 (Nrf-2) that regulates gene expression of a number 
of cellular cardioprotective enzymes, including heme 
oxygenase-1 (HO-1) and thioredoxin-1 (Trx-1)240. Finally, 
H2S increases hypoxia-inducible factor-1 (Hif-1) activity in 
the nematode, Caenorhabditis elegans whereas in 
mammalian has not seen yet241.  
The effect of H2S on MAPK signalling is not clear due 
to the cell type and concentrations used. The MAPK 
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superfamily is composed of three main members, stress-
activated protein kinase/c-JunNH2-terminal kinase 
(SAPK/JNK), p38-MAPK, and ERK. MAPK regulate cell 
proliferation, apoptosis, differentiation, inflammation, and 
cycle progression. The activation of different MAPK 
members by H2S in different types of cells results in inducing 
apoptosis. Infact, H2S induces apoptosis of human aortic 
SMCs via activating ERK242, of insulin-secreting beta cells 
(INS-1E) by the activation of p38 MAPK243 and of human 
derived dopaminergic neuroblastoma cell line (SHSY5Y) by 
downregulation of JNK244. The activation of the same MAPK 
member by H2S in different cells may be responsible for the 
opposite functional consequences. For instance, H2S increase 
endothelial cell proliferation (but also rat vascular smooth 
muscle cells and human colon cancer cells245-246) via 
stimulating a sustained phosphorylation\activation of 
ERK247 and increase the proliferation of nontransformed 
intestinal epithelial cells (IEC-18) cells by upregulation of 
JNK expression248. Instead, the activation of p38 by H2S is 
responsible of survival of human polymorphonuclear cells, 
anti-inflammation of microglial cells and SH-SY5Y cells244; 
249-250.  
Additional kinases are also targets of H2S. In isolated 
hearts subjected to ischemic preconditioning, a brief 
infusion of NaHS stimulates both cardiac AKT and protein 
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kinase C (PKC) activity; this effect has been associated with 
improved cardiac mechanical performance and reduced 
injury251. 
Cell cycle is realized by the progression from G1 
phase to S phase, G2 phase, and M phase (mitosis). Once this 
progression is stopped at any checking point, the cells enter 
G0 phase or the so-called quiescence status. The fate of cells 
going through this cycle is determined at three checkpoints. 
H2S can affect cell proliferation or death by altering the fate 
of the cell going through cell cycle. On epithelial-like cells 
H2S induced cell cycle arrest downregulating cyclin D1 and 
upregulating p21Cip/WAF-1, involved in the control of 
cyclin-cdk activity252-253.  In nontransformed intestinal IEC-
18 cell NaHS (1 mM) promotes the proliferation facilitating 
the cell cycle entry254.  
It has been reported that H2S increase [Ca2+]i by the 
activation of cAMP pathway in primary cultures of brain 
cells, neuronal and glial cell lines, and Xenopus oocytes 
selectively enhance N-methyl-d-aspartate (NMDA)-receptor 
mediated responses and facilitate the induction of 
hippocampal long-term potentiation in the CNS255. Another 
signaling pathway activated by cAMP/PKA in the CNS is the 
PI3K/AKT/p70 ribosomal S6 kinase (p70S6K). NaHS has 
been shown to increase cAMP concentration and expression 
of PI3K, AKT, and p70S6K in isolated rat hippocampal 
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neurons256. In the kidney NaHS reduce renovascular 
hypertension in hypertensive rats lowing level of cAMP, and, 
consequently, of angiotensin II257. Differential effects of H2S 
on cAMP/PKA pathway have been related to the expression 
of different isoforms of AC and/or PDE in different types of 
cells. As regard the effect of H2S on cGMP/PKG pathway it 
was demonstrated that NaHS increased the level of cGMP in 
cultured rat aortic smooth muscle cells inhibiting 
phosphodiesterase (PDE), isoenzymes responsible for the 
hydrolysis of both cGMP and cAMP, without to modify the 
activity of guanylyl cyclase258.  
H2S is a strong reducing agent and may scavenges of 
reactive oxygen species and nitrogen species. H2S 
significantly inhibites ONOO- with a potency like to that of 
glutathione (GSH), a major intracellular antioxidant259. The 
antioxidant property of H2S may also be indirectly realized 
due to its capability in increasing the level of GSH. This could 
partially result from the stimulatory effect of H2S on γ-
glutamylcysteine synthetase and cysteine transport in 
neurons255. 
The antioxidant effects of H2S can affect the 
remodelling or proliferative process of the blood vessels but 
doesn’t affect the vascular contractility260. H2S reduces, also, 
H2O2, ONOO_, and O2, homocysteine-induced, in cultured 
vascular smooth muscle cells261 and hydrogen peroxide and 
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oxLDL-induced cytotoxicity of cultured HUVECs262. H2S also 
can bind to haem proteins as an axial ligand for the 
prosthetic group enhancing the activities of haem-containing 
enzymes in vitro, such as haemoglobin, neuroglobin and 
cytochrome c oxidase, which contributes to some of its 
(patho) physiological effects. H2S reacts with hemeproteins 
in distinct ways: (i) by incorporation of H2S into one of the 
pyrrole rings of the heme, (ii) generating the sulfheme 
derivative, (iii) binding to alternate sites of hemeproteins 
such as cysteine, copper, and zinc ions; or to the ferric iron 
with subsequent reduction of the heme, and (iv) through 
coordination with the ferric heme iron without inducing 
reduction or sulfheme production263. 
 
 
 
Figure 10. Molecular targets of H2S (Li et al., 2011. Annu. 
Rev. Pharmacol. Toxicol.) 
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2.4 Physio- pathological functions of H2S in 
mammalians 
H2S is involved in numerous physiological and 
pathophysiological functions. H2S exerts its biological effects 
at low concentrations and toxic effects at high 
concentrations acting on various biological targets without a 
specific receptors for intracellular signaling264. At 
micromolar (physiological) concentrations, multiple studies 
have demonstrated the cytoprotective (antinecrotic or 
antiapoptotic) effects of H2S which may be related to its 
antioxidant activities. H2S is able to neutralize a variety of 
reactive species including oxyradicals, peroxynitrite, 
hypochlorus acid, and homocysteine261; 265-266. Moreover, 
low levels of H2S exerts cytoprotective effect increasing 
activity of endogenous antioxidant cellular systems as 
glutathione, by the activation/expression of γ-
glutamylcysteine synthetase, N-acetylcysteine and 
superoxide dismutase as demonstrated in primary cortical 
neurons exposed to the excitotoxin NMDA255. Higher 
(millimolar) H2S concentrations are cytotoxic to the cells; 
this is due to free radical and oxidant generation, calcium 
mobilization, glutathione depletion, intracellular iron 
release, as well as induction of mitochondrial cell death 
pathways.  
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H2S and the Cardiovascular System 
In the cardiovascular system H2S induces dilation of 
blood vessels by stimulating KATP channels in vascular 
smooth muscle cells (SMCs)194. H2S shows, also, 
cardioprotection effect during ischemia/reperfusion injury 
in isolated hearts inducing negative inotropic effect and 
reducing central venous pressure by the opened of KATP 
channels in the myocardium267. All these effects can be 
prevented by pretreatment with glibenclamide a classical 
KATP-channel inhibitors, to demonstrate the specificity of H2S 
cardiac effects268. H2S possesses many common features of 
an endothelium-derived hyperpolarizing factor (EDHF). The 
absence of endothelium shifted the H2S concentration-
response curve to the right with the IC50 changed from 136 
to 273 µM. The endothelium-dependent vasorelaxing effect 
of H2S becomes even more significant in small resistance 
arteries. The vasorelaxant effect of H2S is due to the 
activation of both  KATP channels on vascular SMCs and 
charybdotoxin/apamin-sensitive KCa channels in vascular 
endothelial cells194; 269.  
H2S reduces atherogenesis by interfering with 
vascular inflammation250, by inhibiting leukocyte infiltration 
and adhesion270 and by reducing calcification271. Deficiency 
of CSE significantly enhances atherosclerosis development in 
ApoE knockout mice involving disruption of vascular redox 
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status, increased intimal proliferation and inflammatory 
adhesion molecule expression272, and whereas treatment 
with NaHS of the same mice resulted in reduced 
atherosclerotic plaque thanks to reduction of ICAM-1 level in 
circulation and its expression in aortic endothelial cells273. 
H2S can also inhibit calcification and osteoblast 
differentiation of vascular smooth muscle cells that can 
contribute to atherogenesis274. 
H2S play an important role in regulating platelet 
function and thrombosis. It inhibits cyclooxygenase activity 
and collagene-induced platelet aggregation reducing, 
moreover, thromboxane formation275-276. It was 
demonstrate that chronic intake of garlic powder and garlic 
oil also inhibits platelet aggregation in humans277. Several 
reports indicate a potential synergistic effect between NO 
and H2S in controlling various biological responses of 
vascular function. Several study reveale that inhibition of NO 
production by blocking eNOS attenuates H2S mediated 
angiogenic activity and reduces H2S-dependent 
vasorelaxation highlighting the importance of NO in vascular 
H2S signalling, and viceversa278. 
 
H2S and the Nervous System 
H2S exerts important effects in central nervous 
system (CNS) through regulation of neurotransmission and 
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neuromodulation. The potential physiological functions of 
H2S in the brain may include calcium homeostasis, 
potentiation of hippocampal long-term potentiation (LTP), 
suppression of oxidative stress and regulates survival/death 
of neurons. Most of these effects are mediate by activation of 
N-methyl-D-aspartate (NMDA) receptors, normal receptor 
for glutamate, express in both central and peripheral 
nervous systems. H2S selectively enhance NMDA-receptor-
mediated currents by stimulating the production of cAMP in 
primary cultures of brain cells, neuronal and glial cell lines, 
and Xenopus oocytes, which then activates protein kinase A 
(PKA). PKA activated, consequently, phosphorylates the 
NMDA receptor and induces also LTP279.  
Moreover, H2S is able to increase directly glutamate 
secretion280.  The interaction of H2S and NMDA receptors 
affects other neuronal activities, such as epilepsy, 
neuropathic pain, stroke, and Alzheimer’s and Parkinson’s 
diseases. Infact, prolonged activation of NMDA receptors by 
H2S causes calcium overload in cells and leads to their 
death281-284. Thus, inhibition of its production has been 
suggested to be a potential treatment approach in stroke 
therapy. Neuromodulator effects of H2S is, also, due 
increasing release of GABA, a major inhibitory 
neurotransmitter in CNS, that induces upregulation of 
GABAB receptors located at pre- and postsynaptic sites285. 
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The increased GABAergic inhibition by H2S may find its 
application in several situations where the 
excitation/inhibition balance in CNS is disturbed, such as 
seizures and epilepsy, stimuli leading to pain, and cerebral 
ischemia282; 286. In addition, H2S regulates synaptic activity 
inducing Ca2+ wave from neurons287 and increases 
norepinephrine and epinephrine levels in the hippocampus, 
striatum, and brain stem by inhibiting monoamine 
oxidase288.  
 
H2S and Inflammation 
Another area attracting considerable attention is the 
role of H2S in inflammation. H2S has been reported to exert 
both pro-inflammatory and anti-inflammatory effects.  
Among anti-inflammatory effects of H2S there are 
inhibition of proliferation of T lymphocytes289, induction of 
apoptosis in polymorphonuclear cells290, increases 
phagocytosis of bacteria by macrophages and promotes a 
shift of phenotype of macrophages to the “M2”, pro-
resolution state291. Several studies in recent years showed 
that, in some inflammation model as carrageenan-induced 
paw edema and air pouch, injection of rats with NaHS 
inhibited leukocyte infiltration and their adherence to 
vascular endothelium and edema formation. The mechanism 
underlying anti-inflammatory role seems due to activation of 
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KATP channels on endothelial cells and leukocytes because 
they are attenuated by pretreatment with glibenclamide270.  
H2S donors can also down-regulates inflammatory process 
by reducing the expression of a number of proinflammatory 
cytokines, e.g. tumour necrosis factor (TNF)-α, interleukin 
(IL)-1β, IL-8, IL-1α, interferon (IFN)- or proteins, such as 
heme oxygenase (HO) and increasing the anti-inflammatory 
cytokine IL-10. These effects are most likely due to 
suppression of NFĸB activity by H2S234; 292-294. In model of 
neuroinflammation H2S also attenuates LPS-induced 
production and release of NO and TNF-α250. Moreover, H2S 
reduces the gastrointestinal mucosal damage caused by 
nonsteroidal anti-inflammatory drugs. There are a number 
of mechanisms of action underlay this beneficial effects. For 
example, H2S stimulates secretion of bicarbonate in the 
stomach and duodenum, inhibits gastric acid secretion and 
reduces gastric mucosal blood flow and prevents the 
adherence of leukocytes to the vascular endothelium in the 
early stages of gastric injury. Therefore, it has been 
synthetized a new class of NSAID derivatives that release 
H2S. These drugs results the same efficacy in terms of 
retaining anti-inflammatory activity with reduced GI 
toxicity295-297.  
Experimental evidence has showed pro-inflammatory 
role for H2S in various animal models, as hindpaw edema298, 
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acute pancreatitis299, LPS-induced endotoxemia300 and cecal 
ligation and puncture-induced sepsis301. Abnormal synthesis 
or activity of H2S may play a part in septic or endotoxic 
shock because its capacity to open KATP channels. 
Intriguingly, plasma H2S concentrations were also markedly 
increased in patients with septic shock302. Therefore, 
inhibiting the activity of H2S generating enzymes would be 
beneficiary. Infact, in cecal ligation and puncture induced 
sepsis, PPG treatment attenuated inflammatory response by 
reducing neutrophil infiltration and reducing animal 
mortality, wherease NaHS treatment significantly 
aggravated septic inflammatory damages301; 303. H2S has also 
been reported to stimulate the generation of pro-
inflammatory cytokines from human monocytes237. The 
mechanisms for these pro-inflammatory effects of H2S would 
be the releasing endogenous tachykinins such as substance P 
(SP), calcitonin gene-related peptide (CGRP), and neurokinin 
A, and activation of TRPV-1 that mediate neurogenic 
inflammation. A number of factors are involved in 
determining whether H2S is anti-inflammatory or pro-
inflammatory. The first is the dose–response relationships. 
At low, physiological concentrations H2S is predominantly 
anti-inflammatory, whereas at high concentrations H2S 
promotes inflammation, Administration routes (intravenous 
infusion or bolus) may also cause opposite effects. Another 
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important factor is the releasing rate: the slow releasing of 
H2S inhibited inflammation whereas the fast release of H2S 
increased the synthesis of proinflammatory factors304. 
Finally, animal species (rats vs. mice and others), 
inflammation models (regional vs. systemic inflammation), 
and the organ origin of H2S (brain vs. pancreas, etc.) also 
influence the role of H2S in inflammation.  
 
H2S and cell proliferation 
H2S is involved in modulating cell proliferation and 
apoptosis in a variety of cells195. H2S promotes a number of 
cellular signals that regulates metabolism, cardiac function 
and cell survival. Overexpression of CSE in human aortic 
SMCs or treatment with NaHS and other endogenously 
produced H2S inhibited cell growth and induced cell 
apoptosis. The antiproliferative and/or proapoptotic effect 
of H2S treatment may be related to activation of MAPK/ERK 
pathway and its downstream factor caspase-3195. H2S also 
induces stabilization of p53 coupled with the induction of 
downstream proteins such as p21, p53AIP1, induces 
translocation of proapoptotic protein Bax from cytoplasm to 
mitochondria and release of cytochrome c from the 
mitochondria without altering the antiapoptotic protein Bcl-
2243; 305. In addition, H2S act as a cyclin dependent kinase 
(cdk) inhibitor in cell cycle progression in the rat smooth 
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muscle cells305, human lung fibroblast306-307 and oral 
epithelial252 cells by the up-regulation of key cell cycle 
proteins such as cyclin-E and CDC-6 (cell division cycle- 6) 
and by decrease cyclin D1 and p27 involved in cell growth. 
However, H2S inhibit cell proliferation at G1 phase only at 
the early time points (12 and 24 h) such cells might be 
eliminated by the process of apoptosis as indicated by a 
higher incidence of DNA content in the sub-G1 phase, 
wherease  at later time point (48 h)306 follows a partial 
recovery in cell survival. The anti-proliferative and/or pro-
apoptotic effect of H2S may be of importance for the 
prevention of cell proliferation in disorders such as 
atherosclerosis, vascular graft occlusion, and neointimal 
hyperplasia leading to restenosis after angioplasty308. In 
neuroblastoma cell line (SH-SY5Y) NaHS, at concentrations 
lower than 300 µM, suppress rotenone-induced apoptosis by 
inhibition of p38- and c-Jun NH2-terminal kinase (JNK), 
phosphorylation of MAPK, normalization of Bcl-2/Bax levels, 
and reduction of cytochrome c release, caspase-9/3 
activation and poly(ADP-ribose) polymerase cleavage309. 
The same anti-apoptotic effect of NaHS has also been 
observed on rat pheochromocytoma cells (PC12)310. The 
opposite effects of H2S on apoptosis are cell type-specific and 
also depends H2S concentration used. 
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H2S and cancer 
Given the complexity of DNA damage and repair, 
controversy exists on the role of H2S in cancer cell 
proliferation. In colon epithelial cancer cell line NaHS (50–
200 µM) treatment killed the cancer cells stimulating the 
phosphorylation of ERK and p38 MAPK and butyrate also 
induces apoptosis stimulating CBS and CSE expression and 
H2S production311. In another colon cancer cell line, HCT 116 
cells, indeed NaHS (20 µM) promoted their proliferation 
increasing AKT and ERK phosphorylation and reducing 
activity of cyclin dependent kinase inhibitor p21 
(Waf1/Cip1)312. H2S-releasing NSAIDs have also showed to 
be effective and safe in chemoprevention in colon cancer and 
other types of cancers. The mechanism of action of these 
drugs may include inactivation of Nrf2 via sulhydration of 
Keap1, induction of glycolysis within cancer cells and 
induction of apoptosis of cancer cells associated whit 
inhibition of COX-2 activity313. Recently, CBS has emerged as 
a potential therapeutic target in both colon cancer and 
ovarian cancer314-315. In contrast a latest study demonstrates 
that H2S increases nicotinamide phosphoribosyltransferase 
(Nampt) and ATP levels in cancer cells (HepG2, MDA-MB-
231, MDA-MB-435S) inducing intensified glycolysis and 
rapid proliferation. In this way H2S-Nampt pathway protects 
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cells from drug induced damage and it may responsible for 
resistance to therapy316.  
 
Other biological effects 
The opening of the KATP channel also underpins the 
relaxant effect of H2S in colonic317 and eye318, but not 
bronchial smooth muscle319. Because of the crucial role of 
KATP channels in the regulation of pancreatic insulin 
secretion, multiple studies have examined the effect of H2S 
on β-cells, where H2S opens the KATP channels and inhibites 
insulin secretion promoting hyperglicemia320.  
H2S is produced also in the lung and airway tissues, 
via the actions of CSE and CBS express in SMCs, vascular 
SMCs, and vascular endothelial cells321-323, where it 
participates in the regulation of contractility of airway 
smooth muscles and lung circulaiton. It has been suggested 
that decreased CSE expression and H2S levels in pulmonary 
tissues are related to the pathogenesis of asthma. Infact, in 
an animal model of asthma administration of NaHS reduces 
airway inflammation, the number of eosinophils and 
neutrophils in bronchoalveolar lavage fluid airway (BALF), 
the expression of inflammatory genes, and also increased 
peak expiratory flow (PEF) indicating alleviation of airway 
obstruction324. 
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2.5 H2S donors 
With the myriad of purported biological actions of 
H2S there is growing interest in more precise delivery of this 
volatile gas to target tissues in the form of H2S “donating” 
compounds. Pharmacologically useful donors should be 
soluble in aqueous media, should not be toxic, should not 
metabolize quickly and should release H2S in vivo slowly 
over a period of time. 
H2S donating compounds can be divided into three 
general classes: 
 Sulphide salts; 
 Natural compounds (mainly in foods); 
 Synthetic compounds. 
 
Sulfide salts 
Sodium hydrosulfide (NaHS), sodium sulfide (Na2S) 
and calcium sulphide (CaS) are fast delivering compounds. 
They form HS- and H2S immediately upon solvation in 
physiological buffers. These have the advantage of the ready 
availability of high pure H2S concentration, but because H2S 
is rapidly lost from solution by volatilization in laboratory 
conditions their effective residence time in tissues is 
relatively short. Therefore it’s difficult to achieve the desired 
final concentration of H2S and maintain that at constant level 
over a relatively long period. H2S can be released from the 
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solution in a temperature- and concentration-dependent 
manner. At 37°C or below, the concentration of H2S of the 
bath solution was relatively stable. At concentration below 1 
mM, within 30 min H2S amounts decreases of 15% in the 
solution325. Also in vivo, the bolus injection of the animals 
with NaHS/Na2S stock solution creates, immediately, a great 
surge of H2S level, but thereafter, a much lower and 
declining level of H2S is encountered and declining. These 
properties limits their therapeutic potential. 
NaHS is the most used H2S donor for its convenient 
preparation. In solution (water or ethanol) NaHS dissociates 
into Na+ and HS- that in presence of H+ forms H2S. In 
physiological condition (pH 7.4 and temperature of 37°C) 
NaHS solution will yield about one-third of the undissociated 
H2S and the other two-third remains as HS-326. Some effects 
of NaHS cannot be fully explained by H2S. Also the altered 
Na+ concentration or ionic strength as well as the redox 
potential may be associated with NaSH effect, especially at 
high end of the concentrations used.   
Na2S (or IK-1001) is a salt water soluble. In solution, 
it dissociates and generates H2S. Administration of Na2S 
increased blood sulfide and thiosulfate levels and that 
exhaled H2S could be detected327.  
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Natural compounds 
In our daily life, many dietary elements directly and 
indirectly supply H2S to our body so that the advantage of 
this gasotransmitter can be realized, in many cases, without 
conscious thought.  
 
Garlic: Polysulfides and S-ally-L-Cysteine 
Garlic (Allium sativum) has antioxidant, anti-
inflammatory and anticarcinogenic functions. In particular, 
garlic consumption has been correlated with the reduction 
in multiple risk factors associated with cardiovascular 
diseases such as increased reactive oxygen species, high 
blood pressure, high cholesterol and platelet aggregation328. 
Garlic is also effective against bacterial, viral, fungal, and 
parasitic infections and stimulates the immune system329. 
The National Cancer Institute (NCI) set garlic on the top of a 
vegetable pyramid, representing potency in cancer 
prevention330. The benefice pharmacological effects of garlic 
derive from H2S production by the numerous organosulfur 
compounds present such as allicin, allyl sulfides, ajoene, 
polysulfides, as diallyl disulfide (DADS) and diallyl trisulfide 
(DATS); S-alk(en)yl-L-cysteine sulfoxides and S-allyl 
cysteine (SAC)331.  
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Organic polysulfides can interact with either exofacial 
membrane protein thiols or intracellular thiols, such as GSH, 
to form H2S. Benavides et al. demonstrate the capacity of 
garlic extract (DADS and DATS) to produce H2S measuring 
H2S production in real time with a polarographic sensor. In 
particular the release of H2S from DATS is 3 times that from 
DADS236. One of the nonenzymatic mechanisms have been 
proposed to explain the chemical conversion of garlic-
derived organic polysulfides to H2S is the conversion of S-
allyl-glutathione and allyl perthiol to allyl-GSSG and to H2S 
through a sequence of reactions. Another mechanism is the 
direct thiol/disulphide exchange during the interaction of 
polysulfides and GSH332-333. Additional evidences of the H2S 
production from garlic derive by in vivo studies. For 
example, infusion of diallyl disulfide 1.8 mg/kg/min in rats 
increases exhaled H2S334. Moreovwer, in an acute myocardial 
infarction (AMI) rat model, pretreatment of the animals with 
S-allylcysteine protected partially the heart from ischemia 
damage and saved the animals from mortality by about 11% 
and these effects were antagonized by PPG inhibition of 
CSE335. Direct administration of allicin (8 mg/kg) to rats also 
led to lowered systolic blood pressure and triglycerides.  
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Other examples of the therapeutic potential of garlic 
compounds are the reduction of -amyloid fibril formation 
in Alzheimer’s disease transgenic model337; inhibition of 
angiotensin converting enzyme338, prevention of vascular 
remodeling339 and suppression of L-NAME-induced 
hypertension340.  
 
Broccoli and Sulforaphane 
Broccoli (Brassica oleracea) as well as other 
cruciferous vegetables tends to release strong smell of H2S 
when cooked or became rotten. Previous studies have 
reported the health beneficial effects of broccoli on the 
prevention and treatment of hypertension and 
atherosclerotic changes in the SHR stroke-prone rats341. 
These effects of broccoli are largely ascribed to the action of 
sulforaphane, an isothiocyanate compound that exhibits 
anticancer properties. It is rapidly absorbed by humans, 
reaching peak concentrations at 1 h and declining thereafter 
with a half-life of 1.8 hours342. Sulforaphane protects 
vascular smooth muscle cells and endothelial cells from 
oxidative and inflammatory stress and suppresses 
angiogeniesis343-344. In addition, it has neuroprotective and 
anti-inflammatory actions mediated in part through 
activation of heme oxygenase-1 and it provides some 
protection against ischemia reperfusion injury, hemorrhage 
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and serotonin-induced toxicity345. Sulforaphane induces 
death of PC-3 cells (a human prostate cancer cell line) in a 
dose-dependent manner by the activation of p38 MAPK and 
JNK, and this effect is reversed scavenging of free H2S with 
methemoglobin or oxidized glutathione346. 
Another proof of the release of H2S is that sulforaphane in 
human breast cancer MCF-7 cells induces upregulation of 
thioredoxin reductase 1 (EC 1.8.1.9) that reduces 
thioredoxin that is fundamental for H2S synthesis from 3-
MST.  
A related isothiocyanate compound, erucin, is found in high 
levels in rocket salad species (Eruca sativa). 
          
 
Other H2S-food 
Durian (Durio zibethinus Murray) is a notably 
flavorful or pungent fruit, of the Southeast Asia. Durian is 
rich in sulfur compounds, mostly dialkyl polysulfides347 that 
are responsible for its health benefits348. Thousand-Year Egg 
is a Chinese delicacy made from duck, quail, or chicken eggs 
preserved in a mixture of clay, ash, lime, salt, and rice straw 
that is a source of H2S349.   
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Red meat, cheese, milk, fish, soybeans, preserved bean curd 
(stinky tofu), breads, beers, sausages and dried fruit are all 
high-protein foods rich in sulfur amino acids generating H2S 
in the colon following fermentation by colonic bacteria or by 
sulfate-reducing bacteria350.  
 
Synthetic compounds 
In the last years have been developed several H2S 
slow-releasing compounds to allow a long-term sustained 
therapeutic supply of H2S. 
 
GYY4137 
GYY4137 (morpholin-4-ium 4 methoxyphenyl 
(morpholino) phosphinodithioate) is a water-soluble 
molecule that releases H2S slowly and steadily, either in 
aqueous solution or administered to the animal 
(intraperitoneal or intravenous).  
 
 
 
One mmol/l of GYY4137 releases ~40 μmoles of H2S 
in the first 10 min and then releases approximately 40 
μmoles of H2S for hour for the ensuing 80 min when 
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dissolved in acidic (pH 3.0) phosphate buffer wherease in 
buffer at pH 7.4 or 8.5 releases minus of 3 μmoles of H2S in 
the same period. Injection of 133 μmol/kg either 
intrapertioneally (ip) or intravenously (iv) into rats, 
increases plasma H2S levels from ~32 μmol/l to ~80 μmol/l 
in 30 min and this remains elevated (50 μmol/l) for 3 hours. 
H2S concentrations quickly increases in the liver and heart 
for the enduring 20 min, which is even longer in the kidney. 
The slow-releasing property of GYY4137 results in slow 
vasorelaxation without affecting heart rate or myocardial 
contraction of rats. This effect is in part mediated by KATP 
channels. Furthermore, GYY4137 exhibits antihypertensive 
activity in a NG-nitro-L-arginine methyl ester (L-NAME)-
evoked rat hypertension model235. GYY4137, administered 1 
or 2 hours after LPS stimulation, significantly decreases 
secretion of many of the markers of LPS-induced 
inflammation in cultured RAW 264.7 cells including 
nitrate/nitrite, PGE2, TNF-α, IL-1β, IL-6, NF-κB, expression 
of inducible nitric oxide synthase (iNOS), myeloperoxidase 
activity and COX-2351. Anti-cancer effects of GYY4137 have 
been observed in vitro and in vivo. Five-day treatment with 
GYY4137 (400 μmol/l) significantly reduced proliferation of 
breast adenocarcinoma (MCF-7), acute promyelocytic 
leukemia (MV4-11) and myleomonocytic leukemia (HL-60) 
cells; and at 800 μmol/l GYY4137 kills also human cervical 
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carcinoma (HeLa), colorectal carcinoma (HCT-116), 
hepatocellular carcinoma (Hep-G2), osteosarcoma (U2OS), 
without affect survival of non-cancer human diploid lung 
fibroblasts (IMR90 and WI-38). This antiproliferative effect 
of GYY4137 is due to induction of apoptosis and cell-cycle 
arrest in the G2/M. Daily i.p. injection of GYY4137 also 
decreased the growth of HL-60 and MV4-11 tumors 
subcutaneously transplanted in immunodeficient mice352-353. 
 
Cysteine analogs 
The cysteine analogs act as potential substrates for 
endogenous cysteine-metabolizing enzymes increasing H2S 
production at least two-fold. They are: S-propyl cysteine 
(SPC), S-allyl cysteine (SAC, also a derivative of garlic), S-
propargyl cysteine (SPRC) and N-acetyl cysteine (NAC) 354.  
 
 
 
SAC (50 mg/kg/day for 7days) has been shown to low 
mortality and to reduce infarct size in an acute myocardial 
infarction rat model. Inhibition of CSE with PPG eliminated 
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the beneficial effects of SAC, increased infarct size, and 
significantly elevated blood pressure355. Moreover, daily i.p. 
injection of cysteine analogs significantly protected the 
hearts from ischemia reperfusion injury and was associated 
with preserved superoxide dismutase (SOD), glutathione 
peroxidase activity, and tissue GSH levels, while reducing 
lipid peroxidation products354. SPRC attenuated LPS-induced 
deficits in spatial learning and memory in rats and restored 
the LPS deficit in hippocampal H2S levels356. SPRC and SAC 
have also anti-cancer activity. SPRC (1 μM-30 mM) inhibited 
growth of cultured human gastric cancer cells (SGC- 7901) in 
a dose dependent manner, stimulating apoptosis and 
inducing cell cycle arrest at the G1/S phase. In male nude 
mice with SGC-7901 tumors implanted in the flank, SPRC 
and SAC (50 and 100 mg/kg) increased plasma H2S 
concentration, reduced tumor volume, increased apoptotic 
tumor cell number and increased protein expression of Bax 
and p53 while decresed Bcl-2357.  SPRC reduced LPS-induced 
inflammatory response of rat by inhibiting NF-κB activation 
and ERK1/2 phosphorylation and reducing intracellular ROS 
production358. SPRC effects were more pronounced than SAC 
but both act not only as a substrate for H2S by CSE but they 
also up-regulate the enzyme. SPRC and SAC have been 
conjugated with leonurine, an alkaloid in Chinese 
motherwort, which make them more effective to induce H2S 
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production.  Leonurine-SPRC has a cardioprotective effect in 
hypoxic neonatal rat ventricular myocytes by increasing cell 
viability, decreasing LDH leakage, decreasing MDA and 
ROS359.  
 
H2S-releasing hybrid compounds 
These molecules are created by combining a H2S-
releasing moiety with another parent compound with 
known molecular structure and biological functions. The 
purpose to create such a new compound is to enhance the 
functionality and safety of both compositing compounds and 
reduce potential side effects of each part.  
Anethole dithiolethione (ADT) and its main metabolite 
(ADTOH; 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione) 
have been used extensively as a donor of H2S and its ease of 
esterification with other therapeutics has led to a 
considerable variety of H2S “donating” drugs.  
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ACS14 (S-ASPIRIN) 
It is a hybrid between ADTOH and aspirin that 
conserves the cardioprotective efficacy with reduced gastric 
damage. Infact, ACS14 inhibited thromboxane synthesis, 
similar to aspirin, but caused much weaker gastric reactions 
than aspirin did360. This could be due to the antioxidant 
effect of H2S, released from the hybrid. Another related 
compound with S-aspirin is ACS21, S-salicylic acid. Both 
ACS14 and ACS21, limited the development of metabolic 
syndrome in rats induced by GSH depletion (including 
hypertension, endothelial dysfunction, and insulin 
resistance), and protected the heart from I/R damage 
limiting gastric lesion361-362. 
 
 
 
ACS6 (S-SILDENAFIL) 
It is a hybrid between ADTOH and sildenafil. ACS6 
like sildenafil is an effective and selective inhibitor of type 5 
phosphodiesterase (PDE5) and relaxe cavernosal smooth 
muscle, but it is more potent in inhibiting the formation of 
superoxide and expression of p47(phox) and PDE5 than 
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sildenafil363. Normally increased oxidative stress level and 
NOX expression compromise the efficiency of sildenafil in 
treating erectile dysfunction. 
This hybrid will take the advantage of sildenafil-maintained 
cGMP activity and H2S-activated KATP channels and 
suppressed oxidative stress in penile tissues, leading to an 
enhanced potency in relaxing penile cavernosal muscles. 
This hybrid may also find its application in the treatment of 
abnormalities in male reproductive system and urinary 
system.  
 
 
 
ACS84 (S-DOPAS) 
It is a hybrid between H2S-donating dithiolthione 
(ACS1) or allyldisulfide and L-DOPA methyl ester. L-DOPA 
(Levodopa) is extensively used for treatment of Parkinson’s 
disease but it has the adverse effect to induce apoptosis of 
substantia nigra dopaminergic neurons. The presence of H2S 
moiety allows to protect neurons from apoptosis via its anti-
oxidant and anti-inflammatory effects. Moreover, ACS84 
reached the brain is metabolized as early as 1 h after 
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administration to rats intravenously, causing more than 2-
fold increase in brain dopamine and 1.4-fold increase in GSH 
than L-DOPA did364. In fact, ACS84 has a better permeability 
to blood brain barrier than L-DOPA. With cultured human 
microglia, astrocytes, SH-SY5Y neuroblastoma cells, and 
humanTHP-1 U373 cell lines, ACS84 increased intracellular 
H2S levels.  
 
                         
 
 
ACS67 (S-LATANOPROST) 
It is a hybrid between H2S-donating dithiolthione 
(ACS1) and latanoprost. Latanoprost is a synthetic derivative 
of the natural prostaglandin F2 and it is used in the 
treatment of glaucoma because it reduces intraocular 
pressure (IOP) but latanoprost does not protect retina from 
ischemia damage and its tolerance by patients is low. ACS67, 
instead, attenuated the death of cultured retinal ganglion 
cells by increasing GSH levels and decreasing H2O2 
toxicity365. In glaucomatous (carbomer model) pigmented 
rabbits intravitreal injection of ACS67 achieved a greater 
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anti-IOP effect than latanoprost preventing, also, ischemia 
damage thanks to the neuronal protective effect of H2S366.  
 
                                       
                                     
 
 
H2S-NSAIDs 
Another line of research that is producing new 
molecules and exploiting the H2S concept is aimed at 
reducing the toxicity of nonsteroidal anti-inflammatory 
drugs (NSAIDs). H2S donors were shown to reduce the 
severity of NSAID-induced damage in the rat stomach. 
Moreover, NSAIDs decreased endogenous H2S synthesis367-
368. ACS15 (S-DICLOFENAC or ATB337) it is an hybrid 
between ADTOH and diclofenac. Diclofenac is one of the 
NSAIDs that inhibiting inflammation and eliciting analgesia 
but also may cause GI toxicity among other side effects. This 
undesired side effect of NSAIDs has been shown to be 
minimized by H2S donors in the rat stomach367. Therefore 
ACS15 is more potent than diclofenac for anti-inflammatory 
activity and reduces the common side effects of diclofenace, 
such as neutrophil infiltration, leukocyte adherence, and GI 
103 
lesion234; 369, as well as pancreatitis-related lung injury370 
and has no effect on haematocrit. 
 
                   
 
With the same principle and expectations, other H2S-NSAIDs 
have been made: 
ATB-429 is a derivative of mesalamine a drug commonly 
used in the treatment of inflammatory bowel disease (IBD). 
ATB-429 has been shown to be significantly more effective 
than mesalamine in animal models of Crohn’s disease (CD) 
and ulcerative colitis (UC). Moreover, there is also 
considerable preclinical evidence that it is significantly more 
effective in treating the visceral pain associated with IBD371-
372. 
 
 
ATB-346 is a derivative of naproxen, widely used in the 
control of pain in osteoarthritis. However, like other NSAIDS, 
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naproxen carries a significant risk of serious gastrointestinal 
bleeding and cardiovascular effects (e.g., heart attacks, 
elevated blood pressure). In preclinical studies, ATB-346 
exhibited increased effectiveness over its parent drug and a 
remarkable reduction in the gastrointestinal and 
cardiovascular toxicity373. In addition, ATB-346 has been 
shown to have chemopreventive effect in colon cancer374.  
 
 
 
 
 
Others are ATB-343 (derivative of indomethacin) and ATB-
345. All these H2S -NSAIDs, they are metabolized by 
carboxylesterases in the body to slowly generate H2S.  
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AIM 
 
Melanoma is the deadliest form of skin cancer and it 
is rising in incidence. Although in the past 3 years have been 
made notable advances in the understanding the molecular 
pathogenesis of melanoma and its treatment, melanoma 
therapy is still a challenge.  Therefore, it is critical to identify 
other important potential targets in melanoma development 
and progression that are amenable to pharmacological 
inhibition. 
In the last few years, numerous physiological and 
pathophysiological effects have been proposed for the 
gasotransmitter hydrogen sulphide, even its role in cancer 
molecular mechanisms is still unclear. Recently, it has been 
shown that CSE enzyme is expressed in melanoma cell 
lines375 and that CBS enzyme plays a key role in colon and 
ovarian cancer314-315. 
Starting from these evidence, the aim of my PhD project was 
to investigate the role of the metabolic H2S pathway in 
human melanoma.  
To address this issue we: 
(i) evaluated the role of H2S on human melanoma cell 
proliferation and explained its possible mechanism of 
action; 
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(ii) evalueted the role of the endogenous pathway of H2S 
in melanoma development and progression; 
(iii) defined the clinical relevance of the H2S donors in 
order to propose them as new therapeutic agents. 
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METHODS 
 
3.1 Cell culture and reagents 
NHEM was purchased from Lonza (Walkersville, MD, 
USA) and grown in melanocyte growth medium 2 (Lonza). 
The melanoma cell lines B16/F10, Sk-Mel-5 and Sk-Mel-28 
were purchased from IRCCS AOU San Martino – IST (Genua, 
Italy), A375 from Sigma–Aldrich (Milan, Italy). The cell lines 
were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal bovine serum, 2 mmol/l L-
glutamine, 100 mol/l nonessential amino acids, penicillin 
(100 U/ml), streptomycin (100 g/ml) and 1 mmol/l 
sodium pyruvate (all from Sigma–Aldrich). Cells were grown 
at 37°C in a humidified incubator under 5% CO2. The cell line 
PES 43 was isolated from a lung metastases of a patient from 
the National Cancer Institute, G. Pascale Foundation (Scala et 
al., 2006), and cultured in Iscove’s modified Dulbecco’s 
medium (Cambrex Bioscience, Verviers, Belgium) 
supplemented with heat-inactivated 10% fetal bovine 
serum, penicillin and streptomycin (100 units/ml each). 
DATS (LKT Laboratories) was diluted in DMSO to 
produce a stock solution of 10 mM for in vitro experiments; 
GYY4137 (Cayman Chemical, Ann Arbor, MI, USA) was 
solubilized in PBS; PAG, CHH, 3-MP and NaHS (Sigma–
Aldrich) were solubilized in H2O; thioglycine and L-
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thiovaline, a kind gift of Prof. Andreas Papapetropoulos, 
were solubilized in PBS. Vemurafenib (PLX4032) 
(Selleckchem) was solubilized in DMSO. 
 
3.2 Proliferation assays 
Cell proliferation was measured by the 3-[4,5-
dimethyltiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
(MTT) assay or by the 5-bromo-2’-deoxy-uridine assay 
following the manufacturer’s instructions (Roche, Milan, 
Italy). Briefly, for the MTT assay the human melanoma cells 
(A375, Sk-Mel-5, Sk-Mel-28 and PES 43) and the NHEM cells 
were seeded onto 96-well plates (2x103 cells/well) a day 
earlier and successively treated with vehicle or various 
concentrations of different H2S-releasing compounds for 24, 
48 and 72 h before adding 25 l MTT (Sigma–Aldrich; 5 
mg/ml in saline). Cells were then incubated for an additional 
3 h at 37°C. After this time interval, cells were lysed and dark 
blue crystals were solubilized with a solution containing 
50% N,N-dimethyl formamide and 20% sodium 
dodecylsulfate with an adjusted pH of 4.5. The optical 
density of each well was measured with a microplate 
spectrophotometer (TitertekMultiskan MCC/340), equipped 
with a 620-nm filter. None of the compounds tested under 
the same experimental conditions had a cytotoxic effect on 
NHEM. 
109 
 
3.3 Preparation of cellular extracts 
A375 cells (1×106) were seeded in 6-well plates and 
were treated with DATS 100 M for 1, 3 and 6 h or with 
GYY4137 1 mM for 3, 6 and 24 h. To obtein citosolic or 
nuclear extracts the cell pellet was resuspended in 100 μL of 
ice-cold hypotonic lysis buffer (10 mmol/L Hepes, 10 
mmol/L KCl, 0.5 mmol/L phenylmethylsulfonyl fluoride, 1.5 
μg/mL soybean trypsin inhibitor, 7 μg/mL pepstatin A, 5 
μg/mL leupeptin, 0.1 mmol/L benzamidine, 0.5 mmol/L 
dithiothreitol) and incubated on ice for 15 minutes. The cells 
were lysed by rapid passage through a syringe needle 5 
times and centrifuged for 10 minutes at 13 000g. The 
supernatant containing the cytosolic fraction was removed 
and stored at −80°C. The nuclear pellet was resuspended in 
30 μL of high-salt extraction buffer (20 mmol/L Hepes pH 
7.9, 10 mmol/L NaCl, 0.2 mmol/L EDTA, 25% v/v glycerol, 
0.5 mmol/L phenylmethylsulfonyl fluoride, 1.5 μg/mL 
soybean trypsin inhibitor, 7 μg/mL pepstatin A, 5 μg/mL 
leupeptin, 0.1 mmol/L benzamidine, 0.5 mmol/L 
dithiothreitol) and incubated at 4°C for 30 minutes with 
constant agitation. The nuclear extract was then centrifuged 
for 10 minutes at 6000g, and the supernatant was aliquoted 
and stored at −80°C.  
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Whole-cell extracts of A375 cells were prepared after 
lysis in extraction buffer (50 mM Tris 
[tris(hydroxymethyl)aminomethane]/HCl, pH 7.4, 150 mM 
NaCl, 0.1% Triton X-100, 5 mM EDTA 
[ethylenediaminetetraacetic acid], 1 mM Na3VO4, 1 mM 
phenylmethylsulfonyl fluoride, and complete protease 
inhibitor cocktail tablets, Roche). The protein concentration 
was measured by the Bradford method (Bio-Rad, Milan, 
Italy). 
 
3.4 Western blot analysis 
Equal amounts of protein (40 g/sample) from whole 
or nuclear cell extracts were separated by sodium 
dodecylsulfate polyacrylamide gel electrophoresis 
(SDSPAGE) and blotted onto a nitrocellulose membranes 
(Trans-Blot Turbo Transfer Starter System, Bio-Rad). The 
membranes were blocked for 2 h in 5% low-fat milk in PBS 
with 0.1% Tween 20 (PBST) at room temperature. Then the 
filters were incubated with the following primary 
antibodies:  (sc-1643 Santa Cruz Biotechnology, Santa 
Cruz, CA, USA; diluted 1:200); Bcl-2 (2876, Cell Signaling, 
Beverly, MA, USA; diluted 1:1000); caspase 3 (9662, Cell 
Signaling; diluted 1:1000); PARP (9542, Cell Signaling; 
diluted 
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1:1000); p44/42 MAPK (Erk1/2) (9102, Cell Signaling; 
diluted 1:1000); phospho-p44/42 Erk MAPK (Erk1/2, 
Thr202/Tyr204) XP (4370, Cell Signaling; diluted 1:2000); 
AKT (9272, Cell Signaling; diluted 1:1000); phospho-AKT 
(Ser473) XP (4060, Cell Signaling; diluted 1:2000); c-FLIP 
(06-864, Millipore; diluted 1 g/ml); XIAP (R&D Systems, 
Minneapolis, MN, USA; 1 lg/ml); NF-B p65 (F-6) (sc-8008 
Santa Cruz Biotechnology; diluted 1:200); b-actin (Santa 
Cruz Biotechnology; diluted 1:1000) overnight at 4°C. The 
membranes were washed three times with PBST and then 
incubated with horseradish peroxidase-conjugated 
antibodies (Santa Cruz Biotechnology; diluted 1:2000) for 2 
h at room temperature. The immune complexes were 
visualized by the ECL chemiluminescence method and 
acquired by the Image Quant 400 system (GE Healthcare). 
 
3.5 Flow cytometry 
Apoptosis was detected with an annexin V-FITC (BD 
Pharmingen, San Diego, CA, USA) according to 
manufacturer’s instructions. A375 cells were seeded in 35-
mm culture dishes and allowed to attach overnight. The cells 
were treated with DATS (100 M) for 3, 6, 24 and 48 h, 
collected, and washed twice with PBS. Samples were then 
taken to determine baseline and drug-induced apoptosis by 
Annexin V-FITC/propidium iodide (PI) (Beckman Coulter, 
112 
Brea, CA, USA) double staining or PI staining and flow 
cytometry analysis using a FACSCanto II 6-color flow 
cytometer (Becton Biosciences, San Jose, CA, USA). To detect 
early and late apoptosis, both adherent and floating cells 
were harvested together and resuspended in annexin V 
binding buffer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 
2.5 mM CaCl2) at a concentration of 106 cells/ml. 
Subsequently, 5 l of FITC-conjugated Annexin V and 5 l of 
PI were added to 100 l of the cell suspension (105 cells). 
The cells were incubated for 15 min at room temperature in 
the dark. Finally, 400 l of annexin V-binding buffer was 
added to each tube. A minimum of 50 000 events for each 
sample were collected and data were analyzed using 
FACSDIVA software (Becton Biosciences). 
 
3.6 Cell cycle 
Cells were plated in six-well plates at a density of 
5x105 cells/well. Cells were then treated with DATS 100 M 
for 3, 6 and 24 h. Cells were collected, washed twice with ice-
cold PBS buffer (pH 7.2–7.4), fixed with 70% alcohol 
overnight and stained with PI (1 mg/ml) in the presence 
RNAse A (1 mg/ml) for at least 30 min prior to analysis by 
flow cytometry. The flow-cytometric analysis was performed 
using a FACSCanto II and the cycle analysis was performed 
with the MODFIT LT software (Verity Software House). 
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3.7 Electrophoretic mobility shift assay (EMSA) 
Aliquots of total extracts (12 g protein/sample) in 
0.1% Triton X-100 lysis buffer were incubated with 32P-
labeled B DNA probes in binding buffer for 30 min. DNA-
protein complexes were analyzed using non-denaturing 4% 
polyacrylamide gel electrophoresis. Quantitative evaluation 
of NF-B-B complex formation was done using a Typhoon-
8600 imager (Molecular Dynamics Phoshor-Imager, MDP, 
Amersham Biosciences, Piscataway, NJ, USA) and 
IMAGEQUANT software (Amersham Biosciences) (MDP 
analysis). For control of equal loading, F- values were 
normalized to the level of the nonspecific protein-DNA 
complex in the same lane. 
 
      3.8 RNA purification and qPCR 
Total RNA was isolated from cells using the TRI-
Reagent (Sigma–Aldrich, Milan, Italy) according to the 
manufacturer’s instructions, followed by 
spectrophotometric quantization. Final preparation of RNA 
was considered DNA- and protein-free if the ratio between 
readings at 260/280 nm was ≥1.7. Isolated mRNA was 
reversetranscribed by iScript Reverse Transcription 
Supermix for RT-qPCR (Bio-Rad, Milan, Italy). qPCR was 
carried out in CFX384 real-time PCR detection system (Bio-
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Rad) with specific primers using SYBR Green master mix kit 
(Bio-Rad). Samples were amplified simultaneously in 
triplicate in a one-assay run with a non-template control 
blank for each primer pair to control for contamination or 
primer-dimers formation, and the ct value for each 
experimental group was determined. The housekeeping 
gene (ribosomal protein S16) was used as an internal 
control to normalize the ct values, using the 2-Ct formula. 
 
3.9 Transfection 
A375 cells were seeded onto 96-well plates (2x103 
cell/well) and transfected the next day with the human 
CSE/pIRES-EGFP, the human CBS cDNA/pCMV-SPORT6 or 
the human 3-MST/pCI-HA using Lipofectamine 2000 (Life 
Technologies, Milan, Italy). Forty-eight hours after 
transfection, cell proliferation was evaluated by MTT assay 
(see Proliferation assays). Western blot analysis of CSE, CBS 
and 3-MST expression was carried out on whole cell extracts 
to confirm effective gene overexpression (anti-CSE, clone 
2E12-1C10, mouse, 1:500, Novus Biologicals, Ltd; anti-CBS, 
clone H-300, rabbit, 1:500, Santa Cruz Biotechnology); anti-
3-MST (clone NBP1-54734, rabbit 1:500, Novus Biologicals). 
For the silencing experiments, A375 cells were seeded onto 
96-well plates (2x103 cell/well) and transfected the next 
day, according to the manufacturer’s instructions, with CSE 
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Silencer® Select Pre-designed siRNA (Ambion, Carlsbad, CA, 
USA) (sense strand 5’-CUAUGUAUUCUGCAACAAtt-3’, 
antisense strand, 5’- UUUGUUGCAGAAUACAUAGaa-3’); 
human 3-MST siRNA SMART pool siGENOME (Thermo-
Fisher Scientific, Hudson, NH, USA) 
(GGAGAAGAGCCCUGAGGAG, CCGCCUUCAUCAAGACCUA, 
CCACCCACGUCGUGAUCUA, AGAAAGUGGACCUGUCUAA); 
human CBS siRNA SMART pool siGENOME 
(GGAAGAAGUUCGGCCUGAA, GGACGGUGGUGGACAAGUG, 
CACCACCGCUGAUGAGAUC, AGACGGAGCAGACAACCUA). 
Forty-eight hours after transfection, cell proliferation was 
evaluated by MTT assay (see Proliferation assays). 
 
3.10 Generation of Vemurafenib-resistant human 
melanoma cells 
To generate Vemurafenib-resistant human melanoma 
subline, exponentially growing cell A375 were treated with 
increasing concentrations of vemurafenib145. After attaining 
confluence, the cells were repassaged and retreated with 
vemurafenib. Every three passages, the vemurafenib 
sensivity was rideterminate (see Proliferation assays), and 
the process was repeated with higher dose of vemurafenib 
until to obtain vemurafenib-resistant clone cells.  Cells with 
the ability to grow in 1μM of vemurafenib were obtained ~6 
months after the initial drug exposure. Resistant lines were 
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maintained in culture medium in presence of 1μM 
vemurafenib, supplemented every 72h. Then, A375 
vemurafenib-resistant (A375rVem) cell were treated with 
DATS at different concentrations (10μM - 30μM - 100 μM) 
for 24, 48 and 72 h and cell proliferation was evaluated by 
MTT assay (see Proliferation assays). 
 
3.11 Animals 
Animal care was in accordance with Italian and 
European regulations on the protection of animals used for 
experimental and other scientific purposes. Mice were 
observed daily and humanely euthanized by CO2 inhalation if 
a solitary subcutaneous tumor exceeded 1.5 cm in diameter 
or mice showed signs referable to metastatic cancer. All 
efforts were made to minimize suffering. Female C57BL/6 
mice (18-20 g) were from Charles River Laboratories, Inc. 
Mice were housed at the Animal Research Facility of the 
Department of Pharmacy of the University of Naples 
Federico II. 
 
3.12 Induction of subcutaneous B16 lesions 
Mice were subcutaneously (s.c.) injected in the right 
flank with B16-F10 cells (1x105/0.1 ml). When tumors 
reached an average diameter of 2-4 mm, L-cysteine (300 or 
600 mg/kg), DATS (50 mg/kg) or a combination of L-
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cysteine (600 mg/kg),   + PAG (10 mg/kg) or L-cysteine (600 
mg/kg) + CHH (10 mg/kg) was given orally. Control mice 
received only vehicle. Tumor size was measured using a 
digital caliper, and tumor volume was calculated using the 
following equation: tumor volume = Π/6(D1 x D2 x D3) 
where D1 = length; D2 = width; D3 = height and expressed as 
cm3. 
 
3.13 Induction of metastatic melanoma 
Mice were intravenously (i.v.) injected with 5x105 
B16-F10 melanoma cells, in the caudal vein. Starting on the 
1st day after tumor cell inoculation, DATS (50 mg/kg) or L-
cysteine (600 mg/kg), was given orally every day for 14 
days. Control mice received only vehicle. After 14 days the 
lungs were removed and was calculated the percentage of 
metastatic area using ImageJ software. 
 
 
3.14 Patients and specimens 
In all, 102 patients of the National Cancer Institute 
‘Giovanni Pascale’ of Naples have been included in this study 
from 2004 to 2012. All patients were caucasians, and all 
gave their written informed consent according to the 
institutional regulations. This study was approved by the 
ethics committee of the National Cancer Institute ‘G. Pascale’.  
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3.15 Immunohistochemistry analysis 
Tissue samples were retrieved from the paraffin 
blocks of the National Cancer Institute of Naples archives. 
Hematoxylin & eosin staining of a 4-m section was used to 
verify all samples. Immunohistochemical analysis was 
performed on 4-m sections from formalin-fixed, paraffin-
embedded tissues in order to evaluate the expression of CSE 
and CBS. Negative control slides without primary antibody 
were included for each staining. Paraffin slides were 
deparaffinized in xylene and rehydrated through graded 
alcohols. Antigen retrieval was performed with slides heated 
in 0.01 M citrate buffer (pH 6.0) for CSE antibody and 1 mM 
EDTA buffer, pH 8.0 for CBS and 3-MST antibodies, in a bath 
for 20 min at 97°C. After antigen retrieval, the slides were 
allowed to cool. The slides were rinsed with TBS and the 
endogenous peroxidase inactivated with 3% hydrogen 
peroxide. After protein block (BSA 5% in PBS 1X ), every 
slide was incubated with specific primary antibody: anti-CSE 
(clone 2E12-1C10, mouse, 1:1200, Novus Biologicals, Ltd, 
Cambridge, UK; anti CBS (clone H-300, rabbit, 1:500, Santa 
Cruz Biotechnology) anti 3-MST (clone NBP1-54734, rabbit 
1:500, Novus Biologicals). The sections were rinsed in TBS 
and incubated for 20 min with Novocastra biotinylated 
secondary antibody (RE7103), a biotin-conjugated 
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secondary antibody formulation that recognizes mouse and 
rabbit immunoglobulins. Then the sections were rinsed in 
TBS and incubated for 20 min with Novocastra streptavidin-
HRP (RE7104). Finally, peroxidase reactivity was visualized 
using 3,3’-diaminobenzidine (DAB) and the sections 
counterstained with hematoxylin and mounted. Results 
were interpreted using a light microscope. CSE, CBS and 3-
MST expression was evaluated in stained tissue sections by 
two pathologists (G.B, A.A.) in a blinded manner. In each 
sample the number of positive cells was evaluated in 10 non-
overlapping fields using 9400 magnification. Data are 
expressed as the percentage of positive cancer cells over the 
total number of cancer cells. The obtained median value was 
used as cut off for that specific marker (CSE, CBS, 3-MST). 
Therefore in order to be defined as negative, a sample has to 
be equal or below the median value. 
 
3.16 Statistical analysis 
Data from all in vivo experiments are reported as 
mean±SEM unless otherwise noted. Data were analyzed and 
presented using GRAPHPAD PRISM software (GraphPad). 
Significance was determined using Student’s 2-tailed t-test. 
Results were considered significant at P values less than 
0.05 and are labeled with a single asterisk. In addition, P 
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values less than 0.01 and 0.001 are designated with double 
and triple asterisks, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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4.1 Hydrogen sulfide donors inhibit human 
melanoma cell proliferation 
To explain the role of H2S in human melanoma, we 
assessed the effect of several H2S-donors on A375 melanoma 
cell proliferation. All the compounds, but sodium 
hydrosulfide monohydrate (NaHS), inhibited the growth of 
A375 cells in a concentration-dependent manner (Table 4). 
Among all the H2S donors tested, the most potent in 
inhibiting melanoma cell proliferation was DATS, with an 
IC50 of 89 µM.  
Similar results were obtained with all the other cell 
lines: Sk-Mel-5, Sk-Mel-28 and PES 43 whereas didn’t affect 
NHEM proliferation (Table 5). To better confirm that the 
anti-proliferative effect elicited by the H2S-donors was not 
due to an artefact consequent to the hydrogen sulfide-
induced reduction of mitochondrial respiration (MTT assay) 
we performed another proliferation assay, the 5-bromo-20-
deoxy-uridine assay. Results obtained with this assay show a 
greater anti-proliferative effect of DATS (100 µM; –73% P < 
0.001) and of GYY4137 (1 mM; –39%, P < 0.001; Figure 11). 
On the basis of the results obtained with both assays, DATS 
was selected for all subsequent experiments. 
 
To further prove that the anti-proliferative effect of DATS 
was due to release of H2S we had used haemoglobin, an H2S 
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scavenger with whom it forms an inactive complex. Results 
obtained by MTT assay demonstrate a significantly reversion 
of anti-proliferative effect of DATS in the presence of 
haemoglobin (10 M) (Figure 12). 
 
 
 
Table 4. Effect of H2S-donors on cellular proliferation.  
Growth inhibition was measured using the MTT assay and is 
expressed as OD values at 48h. All the compounds used, but NaHS, 
inhibited the growth of A375 cells. Experiments were run in 
triplicate (*P<0.05; **P<0.01; ***P<0.001 vs CTL). 
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Table 5. Effect of H2S-donors on cellular proliferation.  
Growth inhibition was measured using the MTT assay and is 
expressed as OD values at 48h. Both DATS and GYY4137 inhibited 
the growth of PES 43 (A), SkMel 5 (B) and SkMel 28 (C) cells. 
Experiments were run in triplicate (*P<0.05; **P<0.01; 
***P<0.001 vs CTL). 
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Figure 11. Effect of hydrogen sulfide donors on A375 cell 
proliferation.  
Cell proliferation was measured by using the 5-bromo-2'deoxy 
uridine assay and it is expressed as OD values at 48h. Both DATS 
and GYY4137 inhibited the growth of A375 cells. Each experiment 
(n=3) were run in quadruplicate (***P<0.001 vs CTL). 
 
 
 
                 
Figure 12. Reversion of the anti-proliferative effect of DATS 
Growth inhibition was measured using the MTT assay and is 
expressed as OD values at 72h. DATS inhibited the growth of A375 
cells but in the presence of haemoglobin (10 M) its anti-
proliferative effect was significantly reversed. Experiments 
were run in triplicate (***P<0.001 vs CTL; °°° P<0.001 vs DATS). 
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4.2  Hydrogen sulfide donors cause cell cycle 
arrest and induce apoptosis of human melanoma  
In order to clarify whether the antiproliferative effect   
exhibited by DATS was due to a necrotic or apoptotic 
process, A375 human melanoma cells were treated with 
DATS and apoptosis was determined by annexin 
V/propidium iodide (PI) staining, which detects the 
externalization of phosphatidylserine (PS). This dual staining 
distinguishes between unaffected cells (unlabeled; quadrant 
3 Figure 13A), early apoptotic cells (annexin V-positive; 
quadrant 4, Figure 13A), late apoptotic cells (annexin 
Vpositive, PI-positive; quadrant 2, Figure 13A), and necrotic 
(PI-positive; quadrant 1; Figure 13A). Treatment of A375 
cells for 3, 6, 24 and 48 h with DATS (100 M) resulted in a 
time-dependent induction of apoptosis. In particular, at 48 h 
almost all cells (93%) exhibited markers of late apoptosis 
(Figure 13B). This effect was accompanied by a time-
dependent cleavage of caspase 3 and of its substrate 
poly(adenosine diphosphate-ribose) polymerase (PARP) 
(Figure 13C). In addition, DATS treatment of A375 cells 
induced time-dependent accumulation of G0/G1-phase 
populations (Figure 14). As expected, in DATS-treated cells, 
a reciprocal reduction of cell ratio in S and G2/M phases was 
also observed (Figure 14). Therefore, by donating hydrogen 
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sulfide, DATS induces apoptosis and cell cycle arrest of 
human melanoma cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Induction of apoptosis by the H2S-releasing donor 
DATS. 
(A) Cells were treated with DATS (100 µM) at different time 
points  and apoptosis was determined by annexin V/propidium 
iodide (PI) staining, This dual staining distinguishes between 
unaffected cells (unlabeled; quadrant 3, Q3), early apoptotic cells 
(annexin V positive; quadrant 4, Q4), late apoptotic cells (annexin 
V positive, PI positive; quadrant 2, Q2), and necrotic (PI positive; 
quadrant 1, Q1). Treatment of A375 cells for 3-6-24-48 h with 
DATS (100 μM) resulted in a time-dependent induction of 
apoptosis. (B) Quantitative analysis of DATS-induced A375 
apoptosis at various time points showing that at 48 h almost all 
cells (93%) exhibit markers of late apoptosis. (C) Western blot 
analysis of caspase 3 and PARP in A375 whole-cell lysates. A375 
cells were incubated with DATS 100 μM for 1-3-6 hours and a 
time-dependent cleavage of caspase 3 and of its substrate PARP 
was observed. Actin was detected as loading control. 
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Figure 14. Inhibition of cell cycle progression of human 
melanoma cells by DATS. 
DNA histogram shows the accumulation of G0/G1-phase cells 
induced by DATS in A375 cells and cell cycle arrest by the H2S-
releasing donor DATS. Quantitative analysis of cell cycle 
distribution of A375 control-treated or DATS-treated at various 
time points. DATS treatment of A375 cells induced a time-
dependent accumulation of G0/G1-phase populations (▬). As 
expected, in DATS treated cells, a reciprocal reduction of cell ratio 
in S (grey ▭) G2/M-phases (▭) was also observed. 
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4.3  Hydrogen sulfide donors inhibit NF-B 
activation and down-regulate NF-B-dependent anti-
apoptotic genes 
Nuclear factor-B (NF-B) proteins are normally 
sequestered in the cytoplasm in an inactive form closely 
associated with the inhibitory protein inhibitor of kappa 
light chain gene enhancer in B cells-alpha (). Several 
reports have shown that in melanoma the constitutive 
activation of NF-B confers tumor survival capacity and 
avoidance of apoptosis45. 
Western blot analysis carried out on the cytosolic extracts 
obtained from A375 cells treated with DATS 100 M for 15, 
30 and 60 min showed an inhibition of  degradation at 
the earliest time points (Figure 15A). To investigate the 
effect of hydrogen sulfide on NF-B activity, A375 cells were 
treated with DATS (100 M) at different time points (1, 3 
and 6 h; Figure 15B). The A375 cell line was found to display 
a constitutively high NF-B DNA binding activity, as 
compared with NHEM, which was reduced in a time-
dependent manner by DATS. In fact, treatment with DATS 
(100 M) for 3 and 6 h caused a significant (P < 0.001) 
inhibition of NF-B-DNA binding activity by 30 and 76%, 
respectively (Figure 15C). The major NF-B band in A375 
cells consisted of the p50 and p65 subunits. Following on, we 
assessed the expression of three anti-apoptotic proteins, X-
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chromosome-linked inhibitor of apoptosis protein (XIAP), 
FLICE-inhibitory protein (c-FLIP) and B cell lymphoma gene-
2 (Bcl-2), whose expression is modulated by the 
transcriptional activity of NF-B. Western blot experiments 
showed that DATS markedly decreased the expression of all 
the anti-apoptotic genes considered (Figure 16), confirming 
NF-B involvement.  
 
 
 
 
 
 
 
 
 
 
Figure 15. Melanoma cells constitutively express activated 
NF-κB to promote anti-apoptotic and pro-survival signaling. 
(A) Western blot analysis carried out on the cytosolic extracts 
obtained from A375 cells treated with DATS 100 μM  for 15, 30, 
and 60 min shows an inhibition of IκBα degradation at the earliest 
time points. (B) Nuclear extracts from control-treated and DATS-
treated A375 cells collected at 1-3-6 h were analyzed by EMSA for 
NF-κB activation. The A375 cell line displayed a constitutively 
high NF-κB DNA binding activity, as compared to NHEM, that was 
reduced in a time-dependent manner by DATS. These data are 
expressed as arbitrary units and shown in panel C, (***P<0.001vs 
CTL). 
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Figure 16. Hydrogen sulfide donors down-regulate NF-B-
dependent anti-apoptotic genes 
Western blot analysis and relative densitometry of c-FLIP, XIAP 
and Bcl-2 carried out on A375 cells treated with DATS 100 μM for 
1-3-6 h. The hydrogen sulfide donor markedly decreased the 
expression of all the anti-apoptotic genes analyzed; ***P<0.001; 
**P<0.01; *P<0.05 vs CTL. Actin was detected as a loading control. 
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4.4 Expression of CSE, CBS and of 3-MST in 
human melanoma cell lines 
In order to clarify the involvement of the endogenous  
pathway of H2S in melanoma we performed a quantitative 
real-time PCR (qPCR) analysis of the expression levels of 
CSE, CBS and 3-MST genes in NHEM and in a panel of four 
distinct human melanoma cell lines (A375, Sk-Mel-5, Sk-Mel-
28 and PES 43). As shown in Figure 17, the expression of the 
three genes was always very low in NHEM as opposed to 
melanoma cell lines, where CSE, CBS and 3-MST were 
differentially expressed. In particular CSE, but not CBS or 3-
MST, was upregulated in all the cell lines considered, 
although the difference was not statistically significant 
(Figure 17). 
 
 
 
 
 
 
 
 
 
 
 
132 
 
 
 
 
 
 
Figure 17. CSE, CBS and 3-MST qPCR analysis. 
mRNA expression levels of CSE, CBS and 3-MST in NHEM, A375, 
Sk-Mel-5, Sk-Mel-28 and PES 43 cells evaluated by qPCR analysis. 
The expression of the three genes was very low in NHEM. In 
melanoma cell lines CSE, CBS and 3-MST were differentially 
expressed. The housekeeping gene (ribosomal protein S16) was 
used as an internal control to normalize the ct values. Each 
column is the mean ±S.E.M. of at least four independent 
determinations each performed in quadruplicate. ***P<0.001 vs 
NHEM 
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4.5  Overexpression of CSE in A375 cells modifies 
cell proliferation 
On the basis of the results obtained and to better 
elucidate   the role of CSE in melanoma cells proliferation, 
we chose, as a tool, the cell line with the lowest CSE 
expression levels, the A375 melanoma cells. The CSE, CBS 
and 3-MST genes were transiently overexpressed using an 
hCSE cDNA/pIRES2-EGFP, an hCBS cDNA/pCMVSPORT6 or a 
3-MST/pCI-HA construct. Identical empty vectors lacking a 
cDNA insert were used as control. Transfection of the cells 
with CSE cDNA, CBS cDNA, 3-MST cDNA or with the empty 
vectors did not change the morphological characteristics of 
the cells. To determine whether the CSE overexpression 
affected the proliferation of human melanoma cell line, a 
MTT proliferation assay was carried out. Proliferation of the 
CSE-overexpressing cells was inhibited by about 30% (P < 
0.001) as compared with control cells (Figure 18). 
Treatment with hemoglobin, a H2S scavenger, reversed the 
anti-proliferative effect elicited by CSE overexpression, 
confirming the specificity of the effect. When A375 CSE-
overexpressing cells were grown in the presence of L-
cysteine (1 mM) the CSE substrate, the anti-proliferative 
effect was not significantly increased. CBS overexpression 
caused only a small inhibition (P < 0.05), which was not 
further increased when the cells were grown in the presence 
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of L-cysteine. 3-MST overexpression also slightly reduced 
cell proliferation and this effect was significantly increased 
(P < 0.05) in the presence of the enzyme substrate 3-
mercaptopiruvate (3-MP) (10 M) (Figure 18). These data 
show a major role for CSE in melanoma. We also performed 
silencing experiments on the A375 cell line. Cells were 
transiently transfected for 48 h with CSE Pre-designed 
siRNA, human CBS siRNA SMART pool or human 3-MST 
siRNA SMART pool. The negative control siRNA was used as 
internal control. As shown in Figure 19, silencing of the 
genes did not modify cell proliferation.  
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Figure 18. CSE, CBS and 3-MST genes over-expression in A375 
cells. 
CSE over-expression inhibited proliferation of human melanoma 
cells, as demonstrated by the MTT proliferation assay *** P<0.001 
vs Control (CTL). CBS over-expression only slightly (10%,*P<0.05 
vs CTL) inhibited proliferation of human melanoma cells that was 
not further reduced by the addition of L-cysteine (1mM). 3-MST 
over-expression inhibited cell proliferation of about 7% that 
following the addition of the enzyme substrate 3-MP (10 μM) 
reached 15%  (*P<0.05 vs CTL). Hemoglobin (10 µM) reversed the 
anti-proliferative effect induced by enzyme over-expression. Each 
column is the mean ±S.E.M. of 6 independent experiments each 
performed in quadruplicate.  
 
 
 
 
 
 
Figure 19. CSE, CBS and 3-MST silencing in A375 cells. 
CSE, CBS and 3-MST genes silencing did not modify proliferation 
of human melanoma cells, as demonstrated by the MTT 
proliferation assay. Each column is the mean ±S.E.M. of 3 
independent experiments each performed in quadruplicate. 
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4.6  Hydrogen sulfide inhibits the growth of 
melanoma cutaneous in vivo in mice 
To better elucidate the role of H2S in melanoma 
development, we used a well-known murine model of 
melanoma376, which is induced by subcutaneously injecting 
B16-F10 murine cells in C57BL/6 mice. L-Cysteine (300 and 
600 mg/kg), the CSE substrate, was administered orally to 
mice. At day 14 after tumor implantation, a significantly, 
dose-dependent, reduction in tumor volume and weight was 
observed in L-cysteine-treated mice (0.240 ± 0.09 cm3 mean 
tumor volume L-cys 300mg/kg vs control mice 0.365 ± 0.04 
cm3 mean tumor volume, P < 0.05 and 110 ± 9 mg mean 
tumor weight vs control mice 221 ± 30 mg mean tumor 
weight P< 0.01; 0.168 ± 0.03 cm3 mean tumor volume L-cys 
600mg/kg vs control mice 0.365 ± 0.04 cm3 mean tumor 
volume, P < 0.001 and 65 ± 2 mg mean tumor weight vs 
control mice 221 ± 30 mg mean tumor weight, P< 0.001) 
(Figure 20). To verify the specificity of the effect of L-
cysteine we used two selective inhibitors of the enzymes 
CBS and CSE, DL-propargilglicina (PAG) (CSE inhibitor) and 
the acid amminoossiacetico (CHH) (inhibitor of CBS), both at 
a dose of 10mg/kg. These inhibitors were administered 
alone or together with L-cysteine (600 mg/Kg). 
As shown in Figure 21, the L-cysteine alone reduced by 51% 
the volume of the tumor mass (0.134 ± 0.03 cm3 vs 0.348 ± 
137 
0.03 cm3 control mice, P <0.001) and 57% of the weight 
(220.3 ± 48.3 mg vs 532.8 ± 53.5 mg control mice, P <0.01). 
This protective effect was significantly reduced by the PAG 
(0.320 ± 0.05 cm3 vs 0.134 ± 0.03 cm3 L-cysteine alone, P 
<0.001; 497 ± 93.3 mg vs 220.3 ± 48.3 mg L-cysteine alone, P 
<0.01). In contrast, CHH did not alter the effect of cysteine 
(0.211 ± 0.05 cm3; 214.7 ± 32 mg). When administered alone 
both PAG and CHH didn’t significantly alter tumor growth 
(data not shown). 
The tumor growth inhibition obtained by the endogenous-
CSE-derived hydrogen sulfide was mimicked by the 
exogenous hydrogen sulfide delivered to mice following 
administration of DATS. In fact, DATS (50 mg/kg) 
significantly (P<0.001) inhibited tumor growth by 67% 
(0.07 ± 0.001 cm3 mean tumor volume; 88 ± 15,3 mg mean 
tumor weight) as compared with control mice (0.210 ± 
0.004 cm3 mean tumor volume; 358 ± 37,3 mg mean tumor 
weight)(Figure 22). 
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Figure 20. Hydrogen sulfide inhibits tumor growth in vivo. 
 L-cysteine (L-cys 300 mg/Kg, ■) and (600 mg/Kg, ▲), were given 
orally to mice; control mice (●) received vehicle only. Tumor 
volume was monitored on the indicated days. The average tumor 
volume with standard error is plotted against the days after tumor 
implant. L-cysteine significantly reduced tumor volume in dose-
dependent manner (*P< 0.05 vs control; ***P< 0.001 vs control, 
n=8; day 14). The average tumor weight with standard error 
shows that L-cysteine significantly reduced tumor weight in dose-
dependent manner (**P< 0.01 vs control; ***P< 0.001 vs control, 
n=8; day 14). 
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Figure 21. Hydrogen sulfide inhibits tumor growth in vivo. 
L-cysteine (L-cys 600 mg/Kg, ▲), L-cys+PAG (10 mg/Kg) (▼) or 
L-cys+CHH (10 mg/Kg) (♦) were given orally to mice; control mice 
(●) received vehicle only. Tumor volume was monitored on the 
indicated days. The average tumor volume with standard error is 
plotted against the days after tumor implant. L-cysteine 
significantly reduced tumor volume (***P< 0.001 vs control, n=8; 
day 14); the inhibitory effect of L-cysteine was abolished by PAG 
(°°°P<0.001 vs L-cys, n=8) but CHH did not alter the effect of 
cysteine (*P< 0.05 vs control vs control, n=8; day 14). The average 
tumor weight with standard error shows that L-cysteine 
significantly reduced tumor weight (**P< 0.01 vs control, n=8; day 
14); the inhibitory effect of L-cysteine was abolished by PAG 
(°P<0.05 vs L-cys, n=8) but not CHH (**P< 0.05 vs control vs 
control, n=8; day 14). When administered alone both PAG and 
CHH didn’t significantly alter tumor growth (data not shown). 
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Figure 22. Hydrogen sulfide inhibits tumor growth in vivo. 
The H2S-donor DATS (50 mg/Kg, ▲) were given orally to mice; 
control mice (●) received vehicle only. Tumor volume was 
monitored on the indicated days. The average tumor volume with 
standard error is plotted against the days after tumor implant. 
DATS significantly inhibited tumor volume and tumor weight 
(***P< 0.001 vs control, n=8; day 14). 
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4.7  Effect of hydrogen sulfide donors on      
MAPK/ERK and PI3/AKT pathways 
Two of the most frequently deregulated pathways in 
melanoma are mitogen-activated protein kinase 
(MAPK)/ERK and phosphoinositide 3-kinase (PI3K)/AKT73. 
These two pathways play an important role in melanoma 
development and progression and are involved in the 
mechanism of resistance to targeted therapy146.  Therefore, 
we wanted to investigate whether H2S was able to adjust 
these two important "pathways". Western blot experiments 
showed that DATS (100 M) significantly reduced both the 
intensity of the band phospho-AKT and phospho-ERK in a 
time-dependent manner, indicating an inhibition of their 
activation (Figure 23).  Thus, the proapoptotic effects of 
hydrogen sulfide on human melanoma involve a reduced 
activation of the AKT/p-AKT and ERK/p-ERK signaling 
pathways. 
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Figure 23. Hydrogen sulfide donors down-regulate AKT and 
ERK pathways 
Western blot analysis and relative densitometry of phospho- and 
total AKT and ERK in A375 cells treated with DATS 100 μM for 1-
3-6h. Both p-AKT and p-ERK band intensity was time-dependently 
reduced following treatment with DATS (100 µM); ***P<0.001; 
**P<0.01 vs CTL. Actin was detected as a loading control. 
Experiments (n=3) were run in triplicate. 
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4.8  Hydrogen sulfide inhibits A375rVem cell 
proliferation 
To assess whether H2S is efficacy also in conditions of 
resistance to therapy, we generated vemurafenib-resistant 
A375 (A375rVem) melanoma cells. A375 cells harbor the 
BRAF V600E mutation and are sensitive to vemurafenib 
treatment (100 nM). Drug-resistant A375 cells were 
obteined through treatment with increasing concentrations 
of vemurafenib145 (Figure 24). 
Treatment with DATS inhibited significantly the growth of 
A375rVem cells in a concentration- and time- dependent 
manner (Figure 25).  
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Figure 24. Serial dose-response curve showing generation of 
acquired vemurafenib resistance in A375 cells.  
Cells were cultured in increasing dose of vemurafenib (from 3nM 
to 1.3 M) for several passages. Growth inhibition was measured 
using the MTT assay and is expressed as OD values at 72h. In 
parenteral cells A375 vemurafenib inhibited the growth 
significantly in concentration-dependent manner (***P<0.001 vs 
CTL).. In the resulting vemurafenib-resistant cells vemurafenib 
didn’t inhibit cell growth.  
                
 
 
 
Figure 25. Effect of hydrogen sulfide donors on A375rVem 
cell proliferation.  
Growth inhibition was measured using the MTT assay and is 
expressed as OD values at 24h, 48h and 72h. DATS significantly 
inhibited the growth of A375rVem cells in concentration and 
time-dependent manner. Experiments were run in triplicate 
(**P<0.01; ***P<0.001 vs CTL) 
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4.9 Hydrogen sulfide inhibits metastatic   
melanoma in vivo in mice 
To investigate the role of H2S in melanoma 
progression, we performed a murine model of metastatic 
melanoma which is induced by injecting 5x105 cells B16/F-
10 into the tail vein of mice C57BL/6. Through the circle 
cells reach the lungs, where they are visible as metastatic 
foci rich in melanin377. The mice were treated with DATS (50 
mg/kg) or with L-cysteine (1000 mg/kg) while control mice 
received only the vehicle, by orally administration. After 14 
days the lungs were removed and was calculated the 
percentage of metastatic affected area, using the software 
Image J. Results show that treatment with L-cysteine 
reduced of about 65% the development of lung metastases 
compared to control mice (metastatic area: L-cys 4.4% vs 
control mice 70%). Similar effects are shown by DATS which 
reduced of about 67% the metastatic area (metastatic area: 
DATS 3.3% vs 70% control mice) (Figure 26). 
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Figure 26. Hydrogen sulfide reduces lung metastasis growth 
in vivo. 
The H2S-donor DATS (50 mg/Kg) and L-cysteine (1000 mg/Kg) 
were given orally to mice; control mice received vehicle only. L-
cysteine reduced of about 65% the metastatic area; DATS reduced 
of about 67% the metastatic area (A) Gross examination of 
representative lungs (B) Graphical representation of the number 
of lung metastases in treated mice. Image J software was used for 
quantitative analyses.  
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     4.10  CSE, CBS and 3-MST expression in human 
nevi 
Expression of CSE, CBS and 3-MST was evaluated in 
six compound nevi, four junctional nevi and four dysplastic 
nevi. As shown in Table 6, all the dysplastic nevi (100%) 
were positive for CSE, negative for CBS and variable for 3-
MST. Representative immunohistochemical-positive 
expressions of CSE, CBS and 3-MST in nevi and in 
melanomas, but not in lymph node metastases, are shown in 
Figure 27. 
 
4.11 CSE, CBS and 3-MST expression in human 
primitive melanoma and metastases.  
All specimens of primary melanoma analyzed by 
immunohistochemistry (n = 4) were positive for CSE 
expression (Table 7). CBS and 3-MST displayed a variable, 
but always very low, expression level in primary tumor (pT) 
(Table 7). A total of 72 melanoma metastases were analyzed. 
Metastases obtained were either lymph node metastases (n 
= 14) or tissue metastases (n = 58). Tissue metastases were 
distributed as follows: skin (22/58), lung (25/58), liver 
(6/58) and intestinal metastases (5/58). CSE-positive 
metastases were 39% (28/72); among these positive cases, 
93% (26/28) were no lymph node metastases. CBS-positive 
metastases were 30% (22/72); among these positive cases 
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91% (20/22) were no lymph node metastases. 3-MST-
positive metastases were 28% (20/72) none of which were 
lymph node metastases.  
 
 
 
 
Figure 27. CSE, CBS and 3-MST immunohistochemical 
analysis. 
Representative immunohistochemical positive expression of CSE, 
CBS and 3-MST in nevi (A, B, C; 40X);  in melanomas ( D, E, F;  
40X);  in no lymph nodes metastases (G,H, I; 40X).   
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Table 6. CSE, CBS and 3-MST immunohistochemical analysis 
Contingency table of CSE, CBS and 3-MST expression in nevi. In 
rows the frequencies are indicated in absolute values. The 
percentage is reported in brackets. Abbreviations:  “pT” primary 
tumor; (-) no/low expression; (+) high expression.  
 
 
 
 
 
 
 
 
Table 7. CSE, CBS and 3-MST immunohistochemical analysis 
 
Contingency table of CSE, CBS and 3-MST expression in primitive 
melanoma and metastases. All specimens were analyzed by 
immunohistochemistry. The frequencies are indicated in rows in 
absolute values. The percentage is reported in brackets. ‘pT’ 
primary tumor; (–) no/low expression; (+) high expression.  
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DISCUSSION 
Melanoma, the deadliest form of skin cancer, is 
among the most aggressive and treatment-resistant human 
cancers. The incidence of malignant melanoma is rising 
faster, indeed only from 1980 to 2009 the incidence has 
increased fivefold. Each year, more than 132,000 patients 
are diagnosed with this type of cancer378. It is becoming 
clear that melanoma constitutes a heterogeneous group of 
tumors with different patterns of oncogenic mutation, 
overexpression and genomic amplification. The mutation 
rate of melanoma is higher than other aggressive tumors, 
probably due to the involvement of ultraviolet (UV) 
radiation in the genesis of superficial cutaneous 
melanoma53. The most frequent driver mutations in 
melanoma involve genes as BRAF, NRAS, KIT, GNAQ, and 
GNA11. Constitutive upregulation of the MAPK pathway by a 
BRAFV600 mutation occurs in about 50% of melanomas. 
This leads to increased oncogenic properties such as tumor 
cell invasion, metastatic potential, and resistance to 
apoptosis73.  
Multiple cellular pathways have been implicated in 
melanomagenesis, ranging from signal transduction to 
developmental and transcriptional pathways and cell cycle.  
151 
The interactions between the various signalling molecules 
involved in melanoma progression are best viewed as a 
series of links between a number of interconnected nodes. 
If melanoma is diagnosed at an early stage surgical excision 
is curative in approximately 99% of patients. However, later 
stages have poor prognosis due to lack of responsiveness to 
traditional chemotherapeutics13. Over the last 30 years, no 
drug or combination of drugs have demonstrated significant 
impact to improve patient survival for long time. From 1995 
to 2000, the use of cytokines such as interferon and 
interleukin became treatment options. In 2011, new drugs 
were approved by the U.S. Food and Drug Administration, 
including peginterferon alfa-2 for patients with stage III 
disease, vemurafenib for patients with metastatic melanoma 
with the BRAF V600E mutation, the MEK1/2 inhibitor 
trametinib and the monoclonal antibody ipilimumab, 
directed to the CTLA-4 T lymphocyte receptor. Other trials 
for new additional agents and combinations targeting the 
MAPK, PI3K/AKT/mTOR (PI3K), c-kit, are currently in 
progress. Individualized targeted therapy has showed 
response rates, in terms of overall survival, that have never 
been described in melanoma before. However, early 
development of resistance is the major drawback of this 
therapy. It is known that about 50% of patients treated with 
BRAF or MEK inhibitors have disease progression within 6–
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7 months after the initiation of treatment due mostly to 
reactivation of the MAPK pathway. So, metastatic melanoma 
is generally still incurable. Therefore, it is critical to identify 
other important potential targets in melanoma development 
and progression that are amenable to pharmacological 
inhibition.  
In the last few years, several physiological and 
pathophysiological roles have been proposed for the 
gasotransmitter hydrogen sulfide, along with a plethora of 
cellular and molecular targets222. CSE produces H2S from L-
cysteine alone in the presence of pyridoxal 5’-phosphate, 
whereas CBS generates H2S by condensation of L-cysteine 
and other thiols, such as L-homocysteine. Sequential 
reaction by the PLP-dependent enzyme, CAT, and a PLP-
independent enzyme, 3-MST, has also been proposed as a 
potential H2S-producing pathway. CAT forms 3-
mercaptopyruvate from L-cysteine and -ketoglutarate, and 
3-MST subsequently catalyzes the formation of H2S from 3-
mercaptopyruvate in the presence of reducing agents. 
A number of studies have investigated the role of H2S in 
inducing cell death and evidence has been presented that 
this gas can exert both pro- and anti-apoptotic activity in 
cultured cells250; 379. It has been shown previously that CSE is 
expressed in melanoma cell lines375 but the role of the 
hydrogen sulfide pathway has never been investigated. 
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Conversely, a role for this pathway has been proposed in 
colon and ovarian cancer, where it is mainly driven by 
CBS314-315. 
The aim of my PhD project was to evaluate the role of the 
metabolic H2S pathway in human melanoma.  
To address this issue we: 
(iv) evaluated the role of H2S on human melanoma cell 
proliferation and explained its possible mechanism of 
action; 
(v) evaluated the role of the endogenous pathway of H2S 
in melanoma development and progression; 
(vi) showed the clinical relevance of the H2S donors in 
order to propose them as new therapeutic agents. 
Controversy exists on the role of H2S on cancer cell 
proliferation because of the complexity of DNA damage and 
repair. The activation of the H2S pathway has been shown to 
be able to exert both pro- and anti-apoptotic activity in 
cultured cells250; 379. These studies have been conducted on 
immortalized cell lines mainly using NaHS as the exogenous 
source of hydrogen sulfide. The use of NaHS as donor has 
two main drawbacks: (i) the fast kinetics of hydrogen 
sulphide release and (ii) the high concentrations used, often 
in the mM range. These two issues suggest that 
discrepancies (e.g. pro- and anti-apoptotic effect) may lie in 
the choice of the hydrogen sulfide donors used. Sulfide salts 
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such as NaHS and sodium sulfide (Na2S) on addition of water 
generate a burst of hydrogen sulfide within a short period as 
opposed to the organic donors352. Since cell culture takes 
place over a period of hours or days, it is likely that little, if 
any, hydrogen sulphide is present in medium within a short 
time of adding either NaHS or Na2S. It is therefore necessary 
to perform repeated challenge or to use high (mM) doses. In 
a recent comparative study showing differences between 
fast (NaHS) and slow-release (GYY4137) H2S donors, it has 
been demonstrated that only GYY4137 caused a 
concentration-dependent killing of several human cancer 
cell lines352. Therefore, in our study we used both fast 
(NaHS) and slow releasers (DATS, GYY4137, thioglycine and 
L-thiovaline). All the compounds used, except NaHS, 
although with different IC50, inhibited cellular proliferation. 
The most active among the H2S-donors tested was DATS and 
it was selected for the molecular studies since its hydrogen 
sulfide-delivering property had been well characterized236. 
Cytofluorimetric studies demonstrated that the anti-
proliferative effect of DATS was due to its ability to induce 
apoptosis and cell cycle arrest in G0/G1-phase. Caspase-3 is 
the main ‘effector’ caspase in the apoptotic pathway, which 
acts through cleavage of its well-known substrate PARP. The 
finding that DATS induces caspase 3 activation further 
confirmed that H2S triggers apoptosis. Many 
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chemotherapeutic agents cause cell-cycle arrest but not 
apoptosis and this is one of the mechanisms leading to 
chemoresistance. In fact, growth arrest allows cells to repair 
their DNA and limits the efficacy of chemotherapy. Thus, by 
overriding tumor resistance to apoptosis, agents such as 
hydrogen sulphide donors are of great potential value. The 
apoptotic machinery can be controlled, at least in part, by 
NF-B, which regulates transcription of the Bcl-2 family 
members41. Constitutive activation of NF-B has been 
described in melanoma42. The activation of NF-κB promotes 
the multiple steps in melanoma progression such as 
transformation, initiation, promotion, angiogenesis, invasion 
and enhanced metastatic potential of malignant melanoma 
cells43. Moreover, NF-B activated would be responsible of 
resistance of cancer cells to chemotherapeutic agents44. 
Here we show that hydrogen sulphide donors inhibit  
degradation and this effect was associated to the inhibition 
of NF-B nuclear translocation and activation. The issue of 
whether exogenous hydrogen sulfide inhibits233; 358; 380-384 or 
activates238 NF-B signaling pathway has been a matter of 
debate. Indeed, in the relevant literature diametrically 
opposite views exist on the roles of this gas in NF-B 
activation. However, the different experimental settings (in 
vitro versus in vivo) coupled to the different stimuli as well 
as to the protocols used do not allow a clear conclusion to be 
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drawn. It has been shown that the slow-releasing hydrogen 
sulfide donor derivatives of diclofenac234; 295 and aspirin361 
also inhibit NF-B activation. In addition, it has recently 
been shown that hydrogen sulfide inhibits NF-B activation 
in ox LDL-induced macrophage inflammation through both 
sulfhydration of free thiol group on cysteine 38 in p65 
subunit and inhibition of  degradation385. In our study 
and experimental settings we found that hydrogen sulfide 
inhibits  degradation, leading to inhibition of NF-B 
nuclear translocation. 
Thus our results are in line with the inhibitory effect of 
hydrogen sulfide on NF-B activation233; 358; 380-384. The fact 
that NF-B is inhibited by H2S is also supported by the 
finding that treatment with hydrogen sulfide donors greatly 
decreased the expression of the anti-apoptotic proteins c-
FLIP, XIAP and Bcl-2. Indeed, these proteins are known to be 
transcriptionally regulated by NF-B42. 
To evaluate the involvement of the hydrogen sulfide 
pathway in melanoma, we analysed the expression of the 
enzymes involved in H2S synthesis, CBS, CSE and 3-MST, in 
several melanoma cell lines, widely used in the relevant 
literature. All the melanoma cells selected expressed CSE, 
CBS and 3-MST differently. Whereas CSE expression was 
higher in all melanoma cells analysed as compared with 
NHEM, CBS expression was enhanced in A375 cells only, and 
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3-MST showed a variable pattern of expression among all 
cell lines. 
Thus, to obtain further insights into the role of these 
enzymes in melanoma we perform a molecular modulation 
study selecting as a tool the A375 cell line. Overexpression of 
CSE in A375 inhibited cellular proliferation (50%). 
Treatment with hemoglobin, a hydrogen sulfide scavenger, 
reversed the anti-proliferative effect elicited by CSE 
overexpression, confirming the specificity of the effect. CBS 
overexpression caused only a small inhibition of cell 
proliferation (about 10%) that was not further increased by 
the addition of L-cysteine. The same magnitude of effect, 
about 8%, was observed following 3-MST overexpression. 
Addition of 3-MP, the enzyme substrate, increased the anti-
proliferative effect up to 15%. Therefore, these results 
underline the primary role of CSE versus CBS and 3-MST.  On 
the other hand, the silencing of all three enzymes did not 
modify cellular proliferation, implying that reduction of the 
basal endogenous level of H2S production does not affect cell 
survival, or a compensatory mechanism may intervene.  
To support these results, we developed a translational in 
vivo pre-clinical approach. For this purpose we used an 
animal model that recapitulates human cutaneous 
melanoma progression, the spontaneous C57BL/6-derived 
B16 melanoma cell line376 because it is well-established and 
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is a widely used tumor model. We demonstrated that L-
cysteine, the natural substrate of CSE, significantly reduced 
tumor volume and this effect was completely abolished by 
PAG, the selective CSE inhibitor, but not CHH, the CBS 
inhibitor. To further support our in vitro findings we also 
used DATS in vivo. DATS significantly inhibited tumor 
volume development proving that the tumor growth 
inhibition obtained by the endogenous-CSE-derived 
hydrogen sulfide was mimicked by the exogenous hydrogen 
sulfide delivered to mice following administration of DATS. 
To better define the mechanism by which this critical anti-
tumor effect is achieved, we investigated on the possible 
involvement of the MAPK/ERK and the PI3K/AKT pathways. 
These pathways are the two most frequently deregulated 
pathways in melanoma and are also involved in primary and 
secondary resistance to BRAF inhibitors73; 133; 141; 145. We 
have shown that DATS inhibited the phosphorylation-
activation of AKT and ERK. Our results are in agreement 
with other reports showing that exogenous hydrogen sulfide 
downregulates both AKT and MAPK pathways381; 383-384.  
Starting from evidence that MAPK and PI3K/AKT pathways 
are involved in melanoma progression (abnormal 
proliferation, angiogenesis, invasion and metastasis) and 
resistance to therapy with BRAF inhibitor, we have 
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investigated the role of H2S in these conditions mimicking 
these clinical situations. 
Acquired resistance to vemurafenib is a major factor limiting 
successful, long term targeted therapy for patient with 
malignant melanoma142. For this purpose we have generated 
vemurafenib-resistant A375 melanoma cells, harbor the 
BRAFV600E mutation, and we have demonstrate that DATS 
is able to inhibit their proliferation. Therefore, DATS 
overcomes resistance to vemurafenib in vitro. 
Otherwise, we have performed a murine model of metastatic 
melanoma demonstrating that both L-cysteine and DATS, 
significantly, inhibited lung metastasis formation.  
Finally to give another clinical relevance to this study and to 
obtain further insights into the role of the hydrogen sulphide 
pathway in melanoma we analysed the expression of CSE, 
CBS and 3-MST in human tissue samples. The 
immunohistochemical analysis performed on more than 100 
human samples demonstrated that CSE expression increased 
from nevi to primary melanoma, decreased in tissue 
metastases and was absent in lymph node metastases. 
Conversely, analysis of CBS expression revealed that this 
enzyme was absent in dysplastic nevi. Positive CBS 
expression was found in only 25% of the primary 
melanomas analyzed. Therefore, as opposed to other types 
of cancer314;315 CBS does not appear to play an important 
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role in human melanoma. 3-MST expression was always 
extremely variable in the human specimens analyzed (from 
nevi to metastasis). The finding that CSE expression is higher 
in primary melanoma than in distant metastatic melanoma 
suggests the involvement of this pathway in the progression 
of melanoma. These data support our hypothesis that CSE 
derived hydrogen sulfide plays a major role in melanoma. 
Our results are in line with a previous study showing that 
overexpression of CSE in HEK-293 results in the inhibition of 
cellular proliferation and DNA synthesis195.  
Our study demonstrates that in A375 cells, CSE but not CBS 
overexpression induces spontaneous apoptosis and 
exogenous hydrogen sulfide induces apoptosis. This 
apoptotic effect involves: (i) the suppression of pro-survival 
pathways associated to NF-B transcription activity as 
demonstrated by the decreased expression of c-FLIP, XIAP 
and Bcl-2 and (ii) the inhibition of the activation of AKT and 
ERK1/2 downstream signalling pathways.  
Moreover, hydrogen sulphide inhibiting simultaneously both 
the MAPK and PI3K/AKT pathways, is effective in the 
treatment of both cutaneous and metastatic melanoma in 
vivo and in inhibiting growth of vemurafenib melanoma 
resistant cells. 
All these data confirm the involvement of hydrogen sulfide 
in melanoma progression.
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In conclusion we have demonstrated, thanks also to the 
evidence acquired with human specimens, the involvement 
of the L-cysteine/CSE/hydrogen sulfide pathway in human 
melanoma. Our study provides proof-of-principle toward 
establishing this pathway as a diagnostic tool or a potential 
therapeutic target in human melanoma. 
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